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Abstract
Lipids represent a diverse array of molecules essential to the cell’s structure, defense, 
energy, and communication. Lipid metabolism can often become dysregulated during tumor 
development. During cancer therapy, targeted inhibition of cell proliferation can likewise cause 
widespread and drastic changes in lipid composition. Molecular imaging techniques have been 
developed to monitor altered lipid profiles as a biomarker for cancer diagnosis and treatment 
response. For decades, magnetic resonance spectroscopy has been the dominant noninvasive 
technique for studying lipid metabolite levels. Recent insights into the oncogenic transformations 
driving changes in lipid metabolism have revealed new mechanisms and signaling molecules that 
can be exploited using optical imaging, mass spectrometry imaging, and positron emission 
tomography. These novel imaging modalities have provided researchers a diverse toolbox to 
examine changes in lipids in response to a wide array of anticancer strategies including 
chemotherapy, radiation therapy, signal transduction inhibitors, gene therapy, immunotherapy or 
a combination of these strategies. The understanding of lipid metabolism in response to cancer 
therapy continues to evolve as each therapeutic method emerges, and this review seeks to 
summarize the current field and areas of unmet needs. 
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Abbreviations
18F-fluorodeoxyglucose (FDG)
2,5-dihydroxybenzoic acid (DHB) 
3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA)
acetyl-coenzyme A (acetyl-CoA) 
acute myeloid leukemia (AML) 
AMP-activated protein kinase (AMPK) 
ATP-citrate lyase (ACLY) 
beta-oxidation (β-Ox) 
black Hole Quencher (BHQ-3)
choline kinase (ChoK)
choline transporters (ChoTs)
cisplatin (CDDP)
7-hydroxy-9H-(1,3-dichloro-9,9-dimethylacridin-2-one  (DDAO)
diacylglycerol (DAG) 
(4′,6-diamidino-2-phenylindole) (DAPI_
elongation-of-very-long-chain-fatty acids (ELOVL) 
endoplasmic reticulum (ER) 
epidermal growth factor receptor (EGFR) 
fatty acid binding protein-4 (FABP-4)
G-protein coupled receptor (GPCR)
glycerophosphocholine (GPC) 
hormone-sensitive lipase (HSL) 
hypoxia inducible factor (HIF) 
Indocyanine green (ICG) 
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isocitrate dehydrogenase-1 (IDH1) 
lipoprotein lipase (LPL)
low density lipoprotein (LDL)
lysophosphatidylcholine (LPC)
magnetic resonance spectroscopy (MRS) 
mass spectrometry imaging (MSI)
matrix-assisted laser desorption ionization (MALDI)
mono-unsaturated fatty acids (MUFAs) 
nanostructure-initiator mass spectrometry (NIMS)
OKN007 (2,4-disulfophenyl-PBN) 
optical coherence tomography (OCT) 
PBN (α-phenyl-tert-butylnitrone) 
peroxisome proliferator-activated receptor alpha (PPARα) 
phosphatidylcholine (PtdCho)
phosphatidylethanolamine (PtdEtn)
phosphatidylinositol (4,5) phosphate-2 (PIP2) 
phosphatidylinositol (PtdIns)
phosphatidylserine (PtdSer)
phosphocholine (PC)
phosphoethanolamine (PE)
Phosphoinositides (PI) 
phospholipase (PL) 
phosphomonoester (PME) 
plasma membrane citrate transporter (PMCT)
polyunsaturated fatty acid (PUFA)
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positron emission tomography (PET) 
protein kinase C (PKC) 
PtdCho-specific PLC (PC-PLC) 
pyropheophorbide-a (Pyro) 
reactive oxygen species (ROS) 
secondary ion mass spectrometry (SIMS)
sphingosine-1-phosphate (S1P) 
stearoyl-CoA desaturase-1 (SCD1)
sterol response element-binding proteins (SREBPs)
total choline (tCho) 
tricarboxylic acid (TCA)
unfolded protein response (UPR)
α-cyano-4-hydroxycinnamic acid (CHCA)
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Introduction
Cancer cells exist in a hyperactive state of growth and use a complex network of lipid 
metabolic pathways to support this growing biomass. Lipids are a broad class of compounds that 
include fatty acids, triglycerides, steroids, phospholipids, and sphingolipids, among others. These 
molecules play critical roles in cellular compartmentalization, structural barriers, communication 
signals, energy storage, and homeostasis. Despite high vascularization, many cancer cells exist in 
regions of nutrient deprivation and tumors have adopted alternative strategies to maintain sources 
of lipid. In some cases the altered lipid metabolic state offers a therapeutic vulnerability, while in 
others, adaptations to intracellular lipid composition can be used by refractory tumors to resist 
therapies. Because these cancer-driven aberrations in lipid metabolism often contrast the 
surrounding tissue, there are several molecular imaging strategies that have been developed to 
monitor tumor margin, stage, and treatment response. 
I. Lipid Metabolism
A. Exogenous Lipid Uptake
De novo lipid synthesis pathways are crucial during embryogenesis and fetal 
development, but, after maturation, cells in most tissues are capable of acquiring sufficient 
circulating lipids to meet their biosynthetic and energetic needs (1-3). Cancer cells can access 
circulating lipids by overexpressing lipid-scavenging proteins. High exogenous lipids are 
associated with local invasive index, and obesity is also correlated with higher cancer incidence 
rates (4). Higher expression of low density lipoprotein (LDL) receptor has been found in 
transformed colorectal cells relative to normal cells (5). The LDL receptor in prostate cancer 
provides a major source of cellular cholesterol and essential fatty acids (6). Breast cancer and 
select sarcoma cells have been observed to secrete lipoprotein lipase (LPL) to release fatty acids 
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from triglycerides in circulating lipoproteins (7). Although macropinocytosis has been identified 
in cancer cells, little evidence exists to suggest that this is a relevant source of exogenous lipid in 
vivo (8). Instead, lipid binding proteins are thought to assist in the capture of lipids from the 
interstitial space and promote invasion (Figure 1), as overexpression of fatty acid binding 
protein-4 (FABP-4) has been observed on the surface of ovarian, prostate, bladder, and renal 
cancer cells (9,10). Fatty acid translocase, also known as CD36, is a long-chain fatty acid 
scavenger that contributes to high mammographic density in subjects at high-risk for breast 
cancer (11). Ovarian cancer cells can siphon free fatty acids from the lipid stores of the omentum 
by activating perilipin-A and hormone-sensitive lipase (HSL) in neighboring adipocytes (12). 
Studies have shown that removal of lipids from culture medium can trigger de novo lipid 
synthesis, emphasizing the dependency on lipids for cell proliferation and the adaptations cancer 
cells make to sustain their growing biomass (13).
B. De Novo Synthesis
Many cancers revert back to de novo lipid synthesis, and the lipogenic pathway is 
composed of many enzymes that are critical for tumor growth (14). Lipid synthesis starts at the 
energetic hub of the cell, the mitochondria, where acetyl-coenzyme A (acetyl-CoA) and 
oxaloacetate are condensed into citrate (Figure 1). Citrate from the TCA cycle can be shunted 
from the mitochondria and broken down by ATP-citrate lyase (ACLY) into acetyl-CoA. 
Cytosolic citrate can alternatively be sourced from the microenvironment by plasma membrane 
citrate transporter (PMCT)(Figure 1) (15). Besides feeding into the rate-limiting step of fatty acid 
synthesis, acetyl-CoA is also critical for histone acetylation and serves as a link between 
metabolic status and gene expression (16,17).
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Acetyl-CoA serves as the 2-carbon building block used for fatty acid synthesis. The 
enzyme FASN combines malonyl-CoA with repeated acetyl-CoA condensations to form 
palmitate. Palmitate is the saturated 16-carbon fatty acid from which most complex fatty acids in 
the body are derived (18). FASN overexpression is associated with poor prognosis in breast 
cancer (19) and FASN inhibitors derived from natural products (e.g. resveratrol) and synthetic 
molecules (e.g. orlistat) are being studied for their anti-neoplastic effects (20). Acetyl-CoA is 
also a synthetic precursor to 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) in the cholesterol 
biosynthesis pathway (Figure 1). Mevalonate is then produced by HMG-CoA reductase, the 
target of the lipid lowering drugs, the statins. The amplification of HMG-CoA reductase in many 
prostate tumors creates a growth dependency on cholesterol, and suggests a possible role for 
statins in treating these cancers (5,21). Mevalonate is also a precursor to farnesyl-diphosphate, 
which can further be processed to cholesterol, or used as a substrate for protein prenylation. 
Isoprenoids from the mevalonate cascade are critical for membrane anchoring and activation of 
the growth-related G-protein subunits Ras (farnesylated), Rho (geranylgeranylation), and many 
others (22) (Figure 1). 
Fatty acids can be chemically modified in many ways to meet the diverse range of 
specialized functions required for cellular function (Figure 1). Stearoyl-CoA desaturase-1 
(SCD1) produces mono-unsaturated fatty acids (MUFAs) from the saturated fatty acid chains 
sourced exogenously or from de novo synthesis. Saturated fatty acid accumulation in the 
endoplasmic reticulum (ER) triggers autophagy-induced apoptosis by activating the unfolded 
protein response (UPR) (23). By modulating MUFA to saturated fatty acid ratios intracellularly, 
SCD1 has a regulatory effect on cell survival and proliferation (24-26). The elongation-of-very-
long-chain-fatty acids (ELOVL) enzymes in the ER are responsible for polyunsaturated fatty 
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acid (PUFA) synthesis (27), as well as the conversion of saturated and monounsaturated fatty 
acids into the very long chain fatty acids (C > 18) that serve as building blocks of sphingolipids 
when combined with ceramide head groups (28). Free fatty acids are stored as triglycerides in 
lipid droplets or packed into the cell membrane as sphingolipids, cholesterol esters, or 
phospholipids. Lipid droplets in breast cancer cells have been found to increase with increasing 
malignancy and to be enriched in polyunsaturated fatty acids, especially arachidonic acid (29) 
Diacylglycerol (DAG) is an important lipid second messenger that also serves as a 
synthetic precursor for both membrane phospholipids and lipid droplet triacylglycerides (30-33). 
Major membrane phospholipids include phosphatidylcholine (PtdCho), 
phosphatidylethanolamine (PtdEtn), phosphatidylinositol (PtdIns), phosphatidylserine (PtdSer), 
among others, and vary in function, location, and relative abundance. The Kennedy pathway of 
phospholipid synthesis describes the addition of polar head-groups to the DAG backbone, and 
enzymes in this pathway are responsible for the accumulation of phosphocholine (PC) and 
phosphoethanolamine (PE) observed in many cancers (34). Choline uptake by choline 
transporters (ChoTs) and phosphorylation by choline kinase (ChoK) have, in particular, been 
consistently linked with increased invasiveness, drug resistance, and overall malignancy (35). 
C. Lipid Mobilization and Usage
Phospholipid and triacylglyceride levels are maintained by the concerted actions of 
catabolic enzymes that mobilize fatty acids from lipid droplets and cell membranes (36). Fatty 
acid release from lipid droplet storage involves lipases that can support aggressive cancer 
phenotypes in a manner similar to the pro-tumorigenic effects of exogenous fatty acids (37). 
Fatty acid release from membrane phospholipids is carried out by the phospholipase (PL) 
enzymes. PLA1 and PLA2 cleave phospholipids at the sn-1 and sn-2 positions, respectively. The 
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PLA2 family of enzymes are the primary producers of arachidonic acid and three major 
subgroups exist: calcium-dependent or cytosolic cPLA2, calcium-independent iPLA2, and 
secretory sPLA2 (38). While cPLA2 has a tumor-supportive role in many cancers, sPLA2 is 
thought to have tumor suppressive-functions (39). In contrast, iPLAs are housekeeping enzymes, 
primarily responsible for mobilizing lipids to maintain membrane integrity and general cellular 
energy metabolism during homeostasis. PLC cleaves phospholipids at the bond between glycerol 
and phosphate and contains pleckstrin homology domains for anchoring and cooperation with G-
protein coupled receptor (GPCR) signaling networks (40). When activated by growth factor 
receptors, PLD hydrolyzes the phospholipid head group (e.g. choline, ethanolamine, inositol, 
serine) to release PA and links growth factor signaling to cell proliferation (32).
Saturated free fatty acids can be broken down into acetyl-CoA to feed into the TCA 
cycle, and some cancers have been found to prefer fatty acid oxidation to pyruvate oxidation, 
even in sufficient glucose and oxygen environments (41). β-oxidation is an important energy 
pathway in prostate cancers, where glycolytic rates are low, and rapid citrate utilization requires 
a constant supply of acetyl-CoA (42). Peroxisome proliferator-activated receptor alpha (PPARα) 
is a transcription factor whose activation triggers breakdown of very long chain fatty acids in the 
peroxisomes, and fatty acid oxidation in the mitochondria. A complex network of interactions 
with PUFAs, namely arachidonic and linoleic acids, regulates PPARα activity (43). Aside from 
their direct signaling functions (44), arachidonic acid is an important substrates for 
cyclooxygenase, lipoxygenase, and cytochrome enzymes that catalyze the production of the 
eicosanoid family of bioactive lipids that have roles in innate immunity, inflammation, 
cardiovascular disease, and cancer (45,46). 
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II. Tumor Progression and Regression
A. Oncogenic Reprogramming
A common feature of cancer cells is the metabolic transition from oxidative 
phosphorylation to glycolysis, during which the rate of glucose consumption far exceeds the 
energy requirements of the cell (14). What initially appears to be wasteful energy utilization is in 
fact a method to feed glucose-derived pyruvate into biosynthesis, including fatty acids (Figure 
2). Glutamine has been identified in some cancers as an alternative energy source that can enter 
the TCA cycle (47) and provide a carbon source for citrate production (Figure 2), however the 
dependency on glutamine for anaplerosis varies considerably even among cancers of the same 
tissue (48,49). This may be due, in part, to heterogeneity in the local tissue microenvironment 
causing gradients in nutrients, oxygen and signaling factors that influence the energetic state of 
cells.
Under hypoxic conditions, solid tumors can become dependent on unsaturated fatty acid 
uptake from serum to prevent ER stress that can arise when rapid proliferation is unmet by 
nutrient availability (50). These exogenous fatty acids can arise from lipolysis in stromal cells in 
a manner comparable to cachexia (23). The recent resurgence of interest in cancer metabolism 
has improved our understanding of the adaptations tumor cells can make when fuel availability is 
variable. These adaptations are only possible because the common driving mutations in cancers 
often have direct involvement in metabolic pathways.
Many of the clinically prevalent oncogenes are capable of altering lipid uptake, 
production, or consumption to gain a competitive growth advantage (Figure 2). The transcription 
factor hypoxia inducible factor (HIF) is a downstream effector of Myc and is tightly regulated by 
the tumor suppressor gene p53. HIF induces FASN induction and lipid droplet formation for 
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energy storage to support the tumor microenvironment (18,51,52). FASN requires the reducing 
agent NADPH, which is produced from the pentose phosphate pathway that often becomes 
upregulated during cancer reprogramming (18). There is further evidence in renal cell carcinoma 
models that HIF2α-dependent lipid storage suppresses the ER stress response promoting tumor 
cell survival (53).  Glutamine uptake in glioma and acute myeloid leukemia (AML) is often 
accompanied or driven by isocitrate dehydrogenase-1 (IDH1) mutations that reroute glutamine 
toward citrate to provide fatty acid and cholesterol precursors independent of the TCA cycle 
(Figure 2) (54,55). In hypoxic environments where glucose metabolism is diverted to anaerobic 
lactate production, mutations in mitochondrial IDH2 provide a continued source of citrate for 
lipid synthesis, by allowing reductive carboxylation of glutamine-derived α-KG (56). The 
oncometabolite 2-hydroxyglutarate is produced by many cancer-specific IDH1 and IDH2 
mutations, and has widespread epigenetic effectors by altering DNA methylation (57-59).
AMP-activated protein kinase (AMPK) serves as an energetic sensor and master switch 
by inhibiting fatty acid synthesis in low energy states and stimulating consumption of fatty acids 
for energy in the mitochondria by β-oxidation (Figure 2). Sterol response element-binding 
proteins (SREBPs) (60) can activate transcription of genes involved in cholesterol and fatty acid 
synthesis and uptake, and are directly downstream of AMPK and the PI3K/Akt/MTOR signaling 
axis that includes many oncogenes (61). Epidermal growth factor receptor (EGFR) mutations are 
common tumor-driving factors that recruit phospholipases (62,63) and ChoKα (64) to the cell 
surface, leading to membrane remodeling and induction of mitogenic signals to drive cellular 
proliferation. Mitogenic growth signals can also come in the form of sterol-derived hormones 
(estrogens, progestogens, and androgens). Release of these sex hormones, their receptor 
expression, and the downstream signaling mediators are all common tumor-driving factors in 
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prostate, breast, endometrial and ovarian cancers (65). Farnesylation of Ras and 
geranylgeranylation of Rho GTPases are essential for downstream signaling through the 
phosphoinositol family of signaling lipids (66,67). Phosphoinositides (PI) comprise 10-20% of 
total cell phospholipids and among that fraction, phosphatidylinositol (4,5) phosphate-2 (PIP2) 
and phosphatidylinositol-4-phosphate constitute approximately 0.2-1% (68-70). This class of 
membrane lipids plays an integral role in proliferation, apoptosis, metabolism and migration, and 
is pivotal to transmembrane signal transduction because it regulates the distribution of receptor 
tyrosine kinases, G-protein-coupled receptors, and adhesion molecules among others (71).
Metabolic disease is a risk factor for many cancer types, promoting insulin resistance, 
hyperactive growth signals, and evasion of apoptosis that help set the conditions for malignant 
transformation (72). Histological tumor grade in the breast is clinically correlated with 
phosphomonoester (PME) accumulation (73), such as PC and PE, detectable by MR 
spectroscopy (74,75). PC promotes survival and mitogenic signaling through downstream 
cascades such as MAPK and Akt (73,76,77). PC can be formed through the actions of the 
enzyme choline kinase, or by phosphatidylcholine specific phospholipase C. Phospholipid 
catabolism can also be a source of other mitogenic second messengers such as DAG, PA, and 
lysophosphatidylcholine (LPC). DAG is released following the cleavage of phospholipids by 
PLC (78), activates protein kinase C (PKC) resulting in the release of intracellular calcium stores 
and subsequent Ca2+-dependent signaling. DAG and PC are also the synthetic precursors to the 
most abundant mammalian membrane phospholipid, PtdCho, whose levels are predictive of 
breast tumor grade, estrogen receptor status, and patient survival (79). It is intuitive to suspect 
that cancers in high adipose tissue use altered lipid metabolism to take advantage of the 
surrounding environment, however evidence of altered lipid metabolism in cancers that arise in 
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low-adipose tissues suggests that deranged lipid metabolism is a universal hallmark of cancer 
pathogenesis.
Variations in lipid composition are likely due to the heterogeneous nature of the tumor 
microenvironment, which is an ever-changing compartment of structural fibers, nutrients, 
cellular waste, and signaling molecules. Interstitial pH, extracellular matrix, bioactive lipids, and 
cytokines can alter the population and function of stromal cells and surrounding tissues. 
Extracellular lactate, the metabolic byproduct of aerobic glycolysis, is capable of transitioning 
tumor-associated macrophages from tumor-suppressive to tumor-supportive phenotypes (80,81). 
Biopsies of colon cancer specimens have been reported to contain high lipid deposition in 
regions of necrosis and infiltrating macrophages (82). These macrophages most likely resemble 
the immune-suppressive “alternatively-activated” phenotype, as classic (interferon gamma-
induced) activation does not enhance lipid phagocytosis in human myeloid populations (83). 
Alternatively-activated macrophages prefer fatty acid oxidation (84) and are thought to have 
critical roles in clearing/remodeling necrotic tissue, recruiting new blood vessels, and regulating 
innate and adaptive immunity (85). 
B. Lipid changes during Apoptosis/Necrosis
The role lipids play in nearly all cell survival pathways emphasizes their importance in 
tumor growth and invasion pathways, but lipid compartmentalization, metabolism, and signaling 
are also intricately involved in cell death pathways. During apoptosis, the release of 
lysophosphatidylcholine (LPC) and sphingosine-1-phosphate (S1P) by PLAs (86) and 
ceramidases (87) respectively, acts as a “find-me” signal to surrounding macrophages (88). Once 
recruited to the dying cell, exposed PtdSer on the apoptotic cell’s surface serves as the “eat me” 
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signal recognized by phagocytes (89). Unlike the organized compartmentalization of apoptotic 
cells into non-immunogenic apoptotic bodies, necrosis is characterized by the breakdown of the 
plasma membrane and release of the cellular contents that often triggers an immune reaction 
(90). Recently, lipid peroxidase networks have been identified as key mediators of cancer cell 
therapy resistance by reversing a non-apoptotic form of cell death known as ferroptosis can be 
induced by lipid peroxide accumulation (91).  Tumor cell response to therapy begins with 
activation of cell stress responses, which can ultimately decide the fate of the cell and 
surrounding tumor. 
Early changes in lipid metabolism have been reported in response to a wide range of 
cellular stresses (92), but lipid mobilization does not necessarily commit a cell to apoptosis (93). 
Many cells undergoing apoptosis produce lipid droplets, although there are exceptions (94), and 
fatty acids are first mobilized from membrane phospholipids by PLA2 activity (92,95). Reactive 
oxygen species (ROS) produced in the mitochondria of apoptotic cells are thought to inhibit the 
catalytically-active thiol groups on β-oxidation enzymes (96), thus free fatty acids are redirected 
into lipid droplets in the form of triglycerides and sterol esters (97,98). Lipid droplet formation in 
cancer may act as a drug reservoir to reduce intracellular concentrations of drug (99), or to 
absorb reactive oxygen species to protect further DNA damage (100). Lipogenesis of saturated 
fatty acids also makes the cell membrane less penetrable to drugs that enter by passive diffusion 
(101). Uptake of triglycerides by macrophages or neutrophils can dampen subsequent immune 
activation (102,103), providing another potential mechanism of immune escape. Ceramide 
accumulation regulates and can even trigger mitochondrial outer membrane permeability to fully 
commit a cell to apoptosis by allowing cytochrome C release to the cytosol (104). Other signs of 
cell stress that precede or arise during apoptosis are the rise in PUFA and glycerophosphocholine 
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(GPC) levels (105-107). These indicate a reprogramming of lipid metabolism and suggest that 
catabolic networks mobilize lipids from membrane phospholipids during this time. Many of 
these observations were first made using magnetic resonance spectroscopy (MRS) to non-
invasively measure lipid resonances of cancer cells undergoing stress responses and apoptosis 
(92).  
III. Imaging Metabolic Lipid Changes
The development of modern imaging techniques allows the detection of several key 
signaling pathways involved in lipid metabolism and its regulation/dysregulation in cancer. The 
ability to detect these pathways non-invasively aids in the discovery of potential targets for 
imaging or interventional therapies. In addition to developing probes to image lipids and 
alterations in lipid metabolism in mechanisms of oncogenesis, we can also image lipid-
dependent or –mediated signaling in response to therapy (108).  
A. Imaging lipids in tumors: MR Spectroscopy
MRS has been extensively employed for the study of biological material (from cell 
extracts, to homogenized tissue, and intact organisms) because it offers a non-invasive method to 
study the native distribution and dynamic nature of many relevant biomarkers of disease and 
therapeutic response. The search for disease-related metabolites requires the suppression of the 
overwhelming fat and water signals observed in proton MR spectra, however much can be 
learned from the diverse species that contribute to these lipid peaks. 
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B.  Choline and choline metabolites
MRS has been essential in the study of lipid metabolism and for the non-invasive 
observation of lipid metabolism in vitro and in vivo.  This is due to the ability to observe a 
number of lipid metabolites in 1H and 31P MR spectra on the basis of chemical shift 
discrimination. Due to the relative insensitivity of MR, observation is limited to soluble or MR-
visible metabolites in the high micromolar to millimolar levels. Lipid metabolites observable in 
31P MR spectra, include the PME, PC and PE and the PDE, GPC and GPE.  In 1H spectra, 
observable lipid metabolites include the total choline (tCho) resonance, a composite resonance 
encompassing free choline, PC and GPC. Thus there is overlap in the information available 
between 31P and 1H spectra, since the choline PC and GPC resonances seen in the 31P spectra are 
also observed in the tCho region of 1H spectra. The PME and PDE resonances report on 
pathways relevant to phospholipid metabolism. PC and PE are generally the anabolic products of 
choline kinase and ethanolamine kinases, although they can also be produced by the actions of 
phospholipase C.  The PDE resonances result from catabolism of phosphatidylcholine and 
phosphatidylethanolamine via the consecutive action of two phospholipases, A2 and 
lysophospholipase or A1.There are numerous excellent reviews on this topic (35,92,109,110), 
and the reader is referred to these for detailed information.  However, it is worth noting that 
consistent elevations in PMEs and tCho have been observed in a wide range of tumors including 
brain, prostate, lung, skin, ovarian and breast (111,112). As a means to monitor therapeutic 
response, tumor choline levels have been measured using MRS in animal (113-115) and human 
tumors (116-120) with mixed results, at least partly due to the technical difficulties associated 
with acquiring choline spectra on a background of high fat in normal breast tissue. The picture is 
further complicated because ChoK is not the only enzyme that contributes to PC accumulation, it 
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can be produced directly by the actions of PLC on PtdCho, or by the hydrolysis of GPC as a 
source of additional choline for subsequent phosphorylation.  Recent MRS applications have 
been used to detect changes in choline metabolism due to IDH mutations in glioma (59,121) 
explore the role of the glycerophosphodiesterase genes GDPD5 and GDPD6 on breast cancer 
cell migration/invasion (122) and profile metabolic changes in response to HIF1 and HIF2 
suppression (123).
C: Imaging lipids in tumors: MR-visible lipids
Proton MRS was originally used to detect MR-visible or mobile lipid signals in cultured 
cells and tumor biopsies. A series of resonances were observed arising from the fatty acryl chains 
in neutral lipids, triglyceride and cholesterol esters, including the terminal methyl groups, the 
methylenes in long chain fatty acids, and olefinic MUFA/PUFA resonances (124-127). MR 
detects only molecules that exist in a local environment with high rotational molecular motion 
and thus the observed signals arise predominantly from mobile or MR-visible lipids, composed 
of triglycerides and cholesterol esters sequestered in lipid droplets. In animal and human tumors, 
the observation of these lipid resonances require the use of short echo time spectroscopic pulse 
sequences due to the relatively short T2 relaxation times of mobile lipids. In vivo MRS studies 
initially used single voxel localization methods such as STEAM and PRESS for assessing the 
MRS pattern of lipids in tumors, due to the simplicity and accuracy of these methods. However, 
multi-voxel spectroscopic methods including chemical shift imaging are increasingly being used 
both in mouse glioma and xenograft models (128,129) as well as in human tumors (130) since 
these methods provide a better assessment of tumor heterogeneity. The presence of intense lipid 
signals from surrounding subcutaneous fat and muscle have been problematic in evaluating lipid 
signals by MRS methods, thus outer volume fat suppression sequences become critical. For this 
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reason, the majority of studies on intra-tumoral lipids have been focused on the brain where 
subcutaneous fat is at a minimum. However, useful insights into human tumor composition have 
still been made in other tumors, despite the problems associated with high fat content in 
peripheral tissue. 
The presence of lipids in human tumors was initially reported by Kuesel et al. (124) 
where a correlation between MR-visible lipids, tumor malignancy and necrosis was observed in 
brain tumors. These initial findings were subsequently confirmed in in vivo imaging studies as 
well as in histologically different brain tumor types (131). An early demonstration of the 
sensitivity of lipid signals for accurate diagnosis of supra-tentorial brain tumors was 
demonstrated by Preul et al. (132) suggesting lipid signals as a potential biomarker for grading of 
astrocytomas. Correlation of lipids with malignancy was also reported in pediatric brain tumors 
(133) and a further study in pediatric brain tumors suggested the presence of lipids as a marker of 
poor survival (134). Taken together, the presence of MR-visible lipid signals seems to be a 
marker for malignancy and poor prognosis. In our recent review on the role of lipids in tumors 
(92) we argued that increased MR-visible lipids in tumors are indicative of a stress response and 
that their localization reflects areas of cellular hypoxia and or necrosis.
MRS methods have been used to assess changes in the metabolic profile of tumors as 
markers of early therapeutic response. Most xenograft and clinical studies have focused on 
evaluating reductions in the total choline or lactate signal as a marker of treatment response 
Changes in lipid signals not only suggest a positive response, but increases in PUFA, a putative 
marker of apoptosis (106), may also aid in understanding the mechanism of cell death induced by 
specific treatments.
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Gene therapy induced changes in lipids
One of the first studies to implement MRS to evaluate changes in metabolism during 
gene therapy reported a progressive increase in the lipid resonance at 1.3 ppm in 9L rat tumors 
that were injected intratumorally with adenoviral HSV-to followed by ganciclovir treatment 
(135). These initial studies were followed by several studies of the HSV-tk positive BT4C 
glioma model treated with ganciclovir (106,129,136), which established accumulation of PUFA 
resonances as a marker of treatment induced apoptosis. The PUFA resonances arise from 
phospholipase A2 activity leading to hydrolysis of phospholipids in the cell membrane (137). 
These studies indicate that early increases in mobile lipid resonances after therapeutic 
intervention may be suggestive of apoptosis and positive treatment response. The temporal 
evolution of these resonances may be variable, with a decrease in lipid resonances during 
formation of scar tissue after cell death and lysis. However, the mode and nature of therapeutic 
interventions could affect changes in lipid resonances. A recent study involving oncolytic viral 
treatment of immunocompetent Syrian hamster carcinomas as well as a patient with 
neuroblastoma reported lower unsaturated fatty acids, as measured from the olefinic resonance at 
5.3 ppm (Figure 3) in responding tumors than in non-responding tumors (138), which appears to 
be an exception to the norm. Unlike previous studies, which resulted in an apoptotic tumor cell 
death after treatment, treatment with oncolytic viruses resulted in multifocal necrosis and a 
substantial cellular inflammatory response. Taken together, these studies indicate that changes in 
PUFA resonances could possibly be used to differentiate apoptosis from necrosis, although 
further data is needed to substantiate this finding. 
A decreased PUFA resonance, in comparison to normal breast tissue, was reported in a 
patient with breast cancer using selective multiple quantum coherence spectroscopy (139). In 
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contrast to most tumors, a decrease in total tumor lipids was observed in pancreatic cancer 
compared to pancreatitis as evaluated by MR studies of patient biopsy samples (140) as well as 
in vivo comparing focal pancreatitis to pancreatic adenocarcinoma (141). Although the exact 
reason for this apparent anomaly is unclear, the pancreatic tumor microenvironment includes 
stromal tissue that comprises up to 80% of the tumor mass (142). Thus, it is possible that the 
dominant factor contributing to the MR visible lipid signal in pancreatic cancer arises from the 
dynamic assortment of extracellular matrix components, infiltrating immune cells, macrophages, 
pancreatic stellate cells, vascular cells, fibroblasts and myofibroblasts.  
Chemotherapy induced changes in lipids
There have been several MRS studies describing alterations in lipid levels in response to 
treatment with cytotoxic agents. Increased triglyceride resonances were observed in the 
malignant MDA-MB-435 breast cancer cell line treated with the anti-inflammatory agent 
indomethacin (143), a drug that has been shown to reduce tumor invasion and inhibit metastasis. 
Similar increases have also been observed in cells treated with antimitochondrial agents and 
other cytotoxic drugs (96,144-148). Treatment of DU145 prostate cancer cells with the 
differentiating agents phenylacetate or phenylbutyrate also led to a time dependent increase in 
lipid signals, accompanied by increased in GPC, indicating cell stress that precedes the induction 
of apoptosis (107,147). Increased apoptosis in BT4C glioma cells after exposure to cisplatin 
resulted in increases in both saturated fatty acids and PUFA resonances (149). Treatment with 
subcytotoxic doses of cisplatin induced similar increases in saturated and total unsaturated fatty 
acid (5.3 ppm) resonances in HER2+ ovarian cancer cells (150) (Figure 4).  Exposure of the 
VEGFR tyrosine kinase inhibitor SU1498 on human U87 glioma cells induced a significant 
increase in lipids with a concomitant decrease in GPC (151). Although cell studies point towards 
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an increase in MR-visible lipid signals in tumors as a marker of response to chemotherapy, 
translation of these findings to in vivo settings have been challenging due to the confounding 
presence of lipid signals from hypoxic/necrotic regions in the tumor or contamination from lipid 
signals outside the tumor. 
Many factors influence in vivo MRS and make it difficult to predict whether it will 
provide useful biomarkers for new therapeutic interventions. For example, the PI3K/mTOR 
inhibitor voxtali in the presence or absence of temozolomide directly alters the phosphorylation 
of the phospholipid PtdIns in glioblastoma tumors, but causes no detectable changes in 1H MR 
spectra, even though hyperpolarized 13C MRS showed reduced conversion of pyruvate to lactate 
(152). Nevertheless, many studies have successfully evaluated changes in lipid signals in 
response to chemotherapy in tumor xenografts. The efficacy of etoposide, a topoisomerase 
inhibitor, was tested on a murine lymphoma model and a significant increase in the 1.3 ppm 
methylene mobile lipid resonance was noted following etoposide-induced apoptosis (153). 
Treatment of F98 rat gliomas with the choline kinase inhibitor MN58b resulted in a significant 
increase in both saturated (1.3 ppm) and polyunsaturated (2.8 ppm) fatty acids (Figure 5) that 
correlated with increased treatment-induced apoptosis (114). Similar increases in saturated and 
polyunsaturated lipid resonances were observed in GL261 glioma tumors in mice treated with 
temozolomide (128) (Figure 6).  In contrast, treatment of C6, RG2, and GL261 glioma models 
with the nitrones, PBN (α-phenyl-tert-butylnitrone) and OKN007 (2,4-disulfophenyl-PBN) 
resulted in a decrease in lipid resonances after treatment, which was attributed to a decrease in 
necrosis and normalization of the metabolic profile rather than the increase in apoptosis 
generally reported in tumor treatment studies (154). Increases in neutral lipid resonances were 
also correlated with tumor growth arrest and treatment response in a mouse model of HER2+ 
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ovarian cancer treated with cisplatin (150). No changes in total choline were noted in this study, 
as the authors found changes in neutral lipids to be a more sensitive marker of treatment 
response.
Radiation therapy induced changes in lipids
Radiation therapy is one of the most commonly used therapeutic strategies for solid 
tumors in the clinic. Although several studies point towards increased lipid resonances in 
radiation-induced necrosis, relatively few studies have evaluated changes in lipid resonances as a 
marker of early response to radiation therapy. Cervical cancer biopsy samples obtained from 
patients treated with radiation therapy were studied by HR-MAS, which revealed a direct 
correlation between the degree of apoptosis and lipid resonances (155) confirming the 
observations made in cell and xenograft studies. A xenograft model of non-Hodgkin’s diffuse 
large B cell lymphoma treated with radiation th rapy demonstrated a significant increase in both 
mono and unsaturated lipid resonances within 3 days of treatment (156). The increase in lipid 
resonances corresponded with histology findings of increased apoptosis and oil red O staining, 
supporting the idea that unsaturated (PUFA) lipid accumulation is a marker of therapy induced 
apoptosis. 
D. Positron Emission Tomography
Positron emission tomography (PET) measures the gamma rays produced when an 
electron collides with a positron emitted from a beta-decaying nucleus. PET scans require the 
administration of a radioactive substrate, but the high sensitivity of PET means that only tracer 
levels of radiolabeled material are needed. For tumor imaging, 18F-fluorodeoxyglucose (FDG) is 
by far the most commonly employed PET tracer (Figure 7). FDG exploits the enhanced aerobic 
glycolysis observed in many tumors, a phenomenon known as the Warburg effect. 
Page 23 of 128
http://mc.manuscriptcentral.com/nbm
NMR in Biomedicine - For Peer Review Only
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Peer Review Only
24
Overexpression of plasma membrane glucose transporters and hexokinase activity rapidly 
internalize FDG and phosphorylate it in the first step of glycolysis. This reaction traps FDG-6-P 
in the cell, but the substrate is unable to be metabolized further. FDG-PET is widely used 
clinically for the staging of primary tumors, but because of the ability of PET to perform a full-
body scan, it is also important for the detection of metastases. FDG-PET can also be used to 
monitor tumor regression post-therapy, and has been used in several instances to monitor FASN 
inhibitor therapies due to the link between glycolysis and fatty acid synthesis (157,158). One 
caveat is that it is difficult to assess enhanced FDG tumor uptake in tissues with high glucose 
utilization (e.g. brain and heart) or in organs of excretion (e.g. kidney and bladder). There is also 
the potential for background labeling in metabolically active cells, such as lymphocytes in sites 
of inflammation. Furthermore, some tumors, such as the prostate, are not FDG avid and have 
relatively low uptake.
A promising alternative to FDG for tumor lipid imaging is 18F or 11C labeled choline 
(Figure 7). This strategy relies on the upregulation of choline transporters and ChoK in tumor 
cells. The concerted action of these components achieves tumor tissue contrast by rapidly 
internalizing and phosphorylating the choline mimetic radioligands. Choline PET is becoming 
more widely used for tumor detection, especially in the prostate (159) but also in other tumors 
such as gliomas (160). Choline PET has also been used to track tumor recurrence, metastasis, 
and response to chemo and radiotherapy (161-164). One challenge facing choline PET is the 
discrepancy between labeled choline tracer uptake and steady state metabolites observed using 
MRS (165). This could be due to intrinsic differences between choline transport and 
phosphorylation that manifest as differences in tracer uptake relative to steady-state levels, but it 
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could also be due to alternative pathways such as metabolism of the choline tracers in other 
organs such as liver (166).
The low FDG avidity of prostate tumors is linked to their metabolic preference for β-
oxidation of fatty acids, rather than glutaminolysis or glucose metabolism, as a primary energy 
source (42). A variety of 18F-labeled fatty acid analogs have been synthesized (Figure 7), and the 
metabolism of these probes effectively trap the radiolabel specifically in cells with high usage of 
β-oxidation (167,168). In metabolizable probes, labeling at the hydrophobic end of the molecule 
allows these probes to be consumed through β-oxidation. In non-metabolizable probes, chemical 
modifications are nearer to the carboxyl group, which still allows cell uptake and potential 
incorporation into phospholipids or triglycerides, but further oxidative metabolism is prevented 
(169). Labeled fatty acid probes, such as BMIPP (Figure 7), have been primarily employed to 
monitor metabolism in tissues with high levels of β-oxidation, mostly cardiac and to a lesser 
extent skeletal muscle (170-176). Use of these probes to study cancer has been limited, even 
though the use of β-oxidation as a potential cancer energy source has been known for decades 
(177,178).  
Although the half-life of 11C is quite short (20 min), it is still possible to observe 11C 
palmitate uptake and distinguish storage in triglycerides vs metabolism by β-oxidation (179,180). 
Regions of high fatty acid synthesis have been imaged using 11C-acetate incorporation into 
palmitate (181), although the intermediate acetyl-CoA has other potential metabolic fates such as 
the Krebs cycle or histone modification. For this reason, 11C-acetate has been used to monitor 
prostate tumors during therapy and recurrent lesions, but is incapable of distinguishing malignant 
tumors from benign hyperplastic nodules (182-185). Several radiolabeled ether lipids containing 
PC moieties (186) have been made (Figure 7) based upon early observations of elevated 
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phospholipid-ethers in neoplastic tissue (187,188). Due to the preferential accumulation and 
retention of these alkylphosphonium analogs, 124I-CLR1404 was developed and recently tested in 
brain tumor PET imaging where a tumor/normal brain signal ratio of 30 was reported (189). 
Replacement of the PET isotope with the radio-ablative 131I-CLR1404 agent improved survival 
in tumor-bearing rodents and provided a novel theranostic platform wherein 124I can assist in the 
planning of 131I therapy.
E. Mass Spectrometry Imaging
Mass spectrometry imaging (MSI) is a powerful modality for the detailed spatial 
detection of protein, metabolite and drug distribution in tissues. MSI consists of a family of 
techniques that includes matrix-assisted laser desorption ionization (MALDI) MSI, secondary 
ion mass spectrometry (SIMS), matrix electrospray-MSI (ES-MSI), and nanostructure-initiator 
mass spectrometry (NIMS). For the detection of lipids, the most commonly used technique is 
MALDI MSI (190), which has a large range of applications and provides a good overall 
combination of spatial resolution, intact molecule sensitivity and probing depth (190). MALDI 
provides a critical platform for the spatial detection of lipids and lipid metabolites, as there is a 
lack of suitable reagents and antibodies for the analysis of tissue lipids in situ (191). 
MSI techniques are invasive procedures, requiring the preparation and embedding of a 
thin tissue slice followed by rasterized destruction by laser or primary ion beams. For MALDI, 
tissue is embedded in a matrix such as gelatin and α-cyano-4-hydroxycinnamic acid (CHCA) or 
2,5-dihydroxybenzoic acid (DHB) (192). Washing the tissues with aqueous solutions of 
ammonium formate or phospholipases prior to embedding can be used to enhance certain lipid 
species and improve signal to noise (191). MSI can detect hundreds of molecules in a single 
sample with a routine spatial resolution of 50−100 μm, and a small molecule resolution as high 
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as 5−10 μm (193). Because matrix deposition is a slow process and the application of a wet 
matrix to tissue can cause metabolite shift, matrix-free techniques using nanoparticle initiators 
have been developed and these often provide simpler spectra to interpret (194,195). These NIMS 
procedures provide comparable lipid profiles, but with improved spatial resolution (196).
MSI has been used extensively to study lipid in primary human tumor tissue as well as 
tumor cell lines and xenografts. In human tissues, a consistent observation of elevated 
phospholipids has been observed in cancer compared to normal tissues. This includes breast 
tumors and invasive ductal carcinomas compared to carcinoma in situ (197-199), gastric cancers 
(200), renal cell carcinomas (201), human lung squamous cell carcinoma (202) and colorectal 
carcinoma (203,204). The most frequent observation is of increased PtdCho in tumors, but 
increases in PtdEtn, PtdIns, and PA hav  also been observed (199,205,206). Some studies have 
demonstrated increases in ether-linked lipids (199). Lyso-phospholipids have been reported to 
increase in colorectal tumors, but decrease in gastric and prostate cancers (200,203,207) (Figure 
8). Fatty acid levels have also been observed to increase in a number of tumors (199), but it is 
uncertain whether these are free fatty acids or acyl components of more complex lipids. 
Studies in tumor xenografts have confirmed the general observations of increased 
phospholipids and ether-linked lipids in tumor tissues. Measurement of choline metabolites in 
breast cancer xenografts using MR spectroscopic imaging combined with MALDI-MSI revealed 
differences in spatial distribution with PC and choline levels concentrated in normoxic tumor 
regions (208). When correlated with the expression of a hypoxia-response element, PtdCho 
elevation was concentrated in hypoxic regions whereas LPC was elevated in necrotic regions 
(192,209). Further studies have indicated distinct microenvironmental lipid distribution with 
higher levels of ether-linked PtdEtn in viable tumor and ether-linked PtdCho in necrotic regions 
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(193). Elongated fatty acyl chain length in phospholipids of human lung squamous cell 
carcinomas was reproduced in mouse xenografts and correlated with the expression of the acyl 
chain elongase ELOVL6 (210). These data demonstrate the role of MSI in identifying distinct 
tumor microenvironments by their molecular signatures.  
While MSI has revealed a number of potential lipid-related cancer markers, there are very 
few studies that have employed MSI lipids to monitor cancer treatment. One recent study has 
identified transient decreases in serum PtdCho and lyso-PtdCho associated with response to 
radiation in head and neck tumor patients (211). A second study has indicated that LPC (16:0) is 
a significant predictor of PSA recurrence in human prostate cancer patients (207). The NIMS 
technique is capable of simultaneous monitoring of drug accumulation and endogenous water-
soluble metabolite distribution (212,213). Adopting this technique to study drugs that target lipid 
metabolism in tumors should be a priority in this field. These data indicate that further 
investigation into the utility of lipid biomarkers to assess treatment response is warranted. 
F. Optical Imaging 
Optical imaging is a cost-effective and relatively easy-to-use imaging modality that 
makes it a valuable tool for non-invasive longitudinal imaging. The range of detectable 
wavelengths is broad enough to allow multiplex imaging, and these principles have been applied 
to a number of medical diagnostic platforms, including flow cytometry, fluorescence 
microscopy, and diffuse optical imaging. In vivo, optical imaging is limited by attenuated light 
penetration through tissue due to scattering and absorption in the visible wavelengths. This is 
partially alleviated by using chromophores that absorb or emit in the near infrared region (675 – 
900 nm) where absorption by hemoglobin, deoxyhemoglobin and water is at a minimum. In 
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addition, several endogenous proteins, such as laminin and elastin, autofluoresce and elevate the 
background signal during in vivo measurements. As a result, the observable depths of optical 
imaging are usually limited to 1 cm or less. Thus in vivo optical imaging has predominantly 
focused on single-channel fluorescence or bioluminescence on a macro level (< 15x 
magnification) in mice or other small animals. Bioluminescence is not practical in clinical 
settings, because it requires transfection with an invertebrate luminescent protein, but it is a 
highly sensitive reporter that, in the field of lipid metabolism, has been adapted to map regions of 
heightened fatty acid uptake (214). Advances in CCD sensitivity has recently sparked renewed 
interest in Cerenkov radiation as an additional source of emitted light that can be detected in vivo 
(215,216). This signal may one day offer functional information concordant with the 
tomographical information provided by PET (217). 
New optical imaging technologies in oncology have largely followed advancements in 
vascular imaging. Before diffuse optical tomography became a subject of interest in 
mammographic screening, the observation was made that absorption of circulating hemoglobin 
changes in an oxygen-dependent manner (218). This was a pioneering study in translational 
optical imaging, but 20 years later routine clinical optical imaging remains limited outside of 
optical coherence tomography (OCT) in ophthalmic applications (219-221). OCT uses a rastered 
application of NIR light and interferometry to produce a 3-D scanning image of the retina. The 
use of NIR wavelengths still limits the application to surface phenomena, less than 1 cm deep in 
the tissue. OCT has also been employed in oncology, most notably to detect the development of 
esophageal tumors (222,223), With regards to lipids, OCT is most commonly used for 
atherosclerotic plaque detection in cadavers and patients, which is based upon its sensitivity to 
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lipid deposits in local vascular sites (224,225). This leads to the possibility for future applications 
of OCT as a method to distinguish lipid levels in treated tumor tissue. 
In small animal optical imaging, enhanced contrast is often provided by the 
administration of exogenous NIR fluorescent compounds. There are a growing number of these 
molecular probes that allow for noninvasive optical imaging of lipid metabolism pathways. The 
probes are generally of three types: passive molecules that are used as blood pool agents and rely 
on leaky vasculature to accumulate at the site of pathology, targeted permanently fluorescent 
molecules that can be taken up selectively as substrates or inhibitors of lipid metabolic pathways, 
and smart quenched fluorescent molecules that can be selectively activated by enzymes. 
Fluorescence imaging using these probes allows for specific and localized detection of metabolic 
activity.  
Indocyanine green (ICG) is a clinically approved blood-pooling agent that has been used 
for tumor detection. Collection of ICG in solid tumors has been attributed to the enhanced 
permeability and retention caused by disordered vasculature and insufficient lymphatic systems 
in tumors (226), however tumor-associated macrophages in lipid-rich regions may have an 
underappreciated role in this phenomenon. In atherosclerotic plaques, ICG has been observed to 
accumulate preferentially in the lipid-rich macrophages in both rabbits and patients (227). MRI, 
PET, and optical imaging of tumor-associated macrophages have been described extensively 
(228-230) and these methods should be used to explore co-localization of lipid profiles with 
immune infiltration in the tumor setting. 
Lipid uptake and synthesis
Lipid uptake and synthesis are essential to the maintenance of mammalian cell 
membranes. For this reason, a constant source of precursors are required to maintain the 
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proliferative nature of the cancer cell. Tumor cells synthesize and accumulate membrane lipids, 
such as PtdCho, at a rate that greatly outpaces the surrounding normal tissue, and this offers an 
avenue that can be exploited for selective delivery of imaging and therapeutic agents. The 
introduction of fluorescently labeled lipid analogs into the tumor microenvironment can also be 
used to visualize lipid scavenger activity. Direct fluorescent labeling of PtdCho has been 
reported using visible fluorophores, so high background in normal tissues is a general feature of 
these approaches (231). A common approach is to employ fatty acid probes to which non-polar 
dyes such as BODIPY have been attached (232). Depending on the metabolic state of the cell, 
these lipid analogs can be incorporated into phospholipids or neutral lipids in lipid droplets. The 
alkylphosphocholine analogs described for PET imaging have also been adapted with BODIPY 
or heptamethine dyes for imaging of tumor margins and draining lymph nodes (233). 
Choline kinase
Choline kinase catalyzes the conversion of choline to PC, and is elevated in several types 
of cancers. Its upregulation has been correlated with the transition of normal breast epithelium 
toward a malignant phenotype, and selective inhibitors have been developed for Phase I clinical 
trials in solid tumors (ClinicalTrials.gov, NCT01215864). Based on these studies, we developed 
a series of fluorescent inhibitors that selectively bind ChoK and emit fluorescence in the near 
infrared optical window (234). The design exploited the structural similarities between ChoK 
inhibitors and cyanine dyes frequently employed for optical imaging, and did not rely on dye 
conjugation to existing inhibitor structures (235). The probe, JAS239, showed elevated uptake in 
tumors that overexpressed ChoK, and more importantly, had reduced uptake in tumors after 
chemotherapy (236).
Phosphatidylinositol signaling pathway
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Many oncogenic signaling pathways are mediated by PtdIns, which makes these lipids 
attractive targets for cancer imaging probes. In order to interrogate the role of these 
phospholipids on cell signaling, Yoon et al. engineered a fluorescent PIP2 sensor to study its role 
in membrane remodeling, regulation of membrane proteins, and regulation of the cytoskeleton  
(236-238). This probe was engineered with the visible fluorophore (2-dimethyl-amino-6-acyl-
naphthaline) optimized for its lipophilic properties, limiting its utility for detection of lipid 
dynamics in vivo. Because IP3 and DAG mediate the release of intracellular calcium and are 
activated by lipid metabolic pathways, optical probes based upon flu-4 or BAPTA can provide 
an indirect means of assessing these bioactive lipids (239-241). DAG can be evaluated directly 
using radiolabeling (242) or using optical techniques such as FRET to detect activated DAG 
intercalation in the plasma membrane (243).  
Phospholipases 
Phospholipases are catabolic enzymes that can be targeted with lipid based quenched 
optical probes that are activated by enzymatic hydrolysis (39). Upregulation of cPLA2 has been 
observed in breast and prostate cancers (112), and elevated levels of PC and 
phosphoethanolamine have been attributed to PLC activation in breast cancer, ovarian cancer 
and melanoma (109). Activatable probes with phospholipid-based structures, a linker that 
regulates enzyme accessibility, a quenchable fluorophore or light-emitting compound, and a 
cleavable quenching domain have been designed as fluorescent agents for quantifying 
phospholipase activity. The advantage of this approach is the enhanced signal to noise available 
from the continuous enzymatic release of fluorescent substrates. Enzyme activated BODIPY 
probes have been employed to examine phospholipase activity in many systems including the 
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digestive physiology of the zebra fish (244-247). While useful for cells, small transparent 
animals and intravital microscopy, the optical properties of BODIPY limit its detection in tissue. 
There are several quenched fluorophores commercially available with emission in the visible 
range. In the NIR range, we developed analogous probes targeting PLA2 and PLC for in vivo 
applications (248). These self-quenching probes were composed of pyropheophorbide-a (Pyro) 
tethered to PtdEtn and a Black Hole Quencher (BHQ-3). While Pyro has an excitation maximum 
excitable Soret band at 418 nm that emits at 660 nm, its absorption peak at 670 with emission at 
725 nm makes it suitable for in vivo imaging. The specificity of these probes to various 
phospholipase isoforms could be modulated by altering the spacer length between Pyro and the 
glycerol backbone. The resulting construct, Pyro-PtdEtn-BHQ, was highly specific to PtdCho-
specific PLC (PC-PLC) both in vitro and in vivo and we used this to detected upregulation and 
activation of this enzyme in DU145 prostate cancer xenografts (Figure 9) (112).  
Arachidonic acid, a PUFA found in the sn-2 position of phospholipids, is mobilized by 
the activity of cytosolic or cPLA2 acting on membrane-associated phospholipids.  The redox 
activity of COX-2 catalyzes the conversion of arachidonic acid to prostaglandins that act as a 
lipid second messenger.  Arachidonic acid is first converted to prostaglandin G2, and then the 
peroxidase activity of COX-2 converts it to the unstable H2 isoform that is converted to one of 
several homologous tissue- and function-specific isoforms of prostaglandins.  It is prostaglandin 
E2 that is notably upregulated in several types of cancer contributing to aberrant signaling (249). 
In order to utilize this signal transduction pathway to image pathogenic events, there are several 
points of interrogation possible: using activatable probes to evaluate COX-2 activity, directly 
measure PGE2 levels with targeted probes, or evaluate activation of further downstream events.  
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Detection of cPLA2 using a cleavable construct requires a probe that contains 
arachidonic acid, to account for the specificity of the enzyme for this fatty acid, as well as a 
small enough head group to fit into the active site.  Previous studies had shown that arachidonic 
acid esterified to visible fluorophores such as 7-hydroxycoumarin were highly specific for 
cPLA2 and displayed similar hydrolysis kinetics to native substrates (250). We adapted this 
caged fluorescence protocol using fluorophores that emit in the red wavelength range (660-680 
nm) to create cPLA2 sensitive probes suitable for in vivo imaging. Probe selectivity could be 
modulated by choice of fatty acids and fluorophores, with DDAO arachidonate performing the 
best in vitro, in cells and tumors. Here, arachidonic acid provided the optimum fatty acid 
substrate for cPLA2 and DDAO (7-hydroxy-9H-(1,3-dichloro-9,9-dimethylacridin-2-one) was 
the most resistant to non-specific aqueous hydrolysis. Probe activation was shown to be 
proportional to cPLA2 expression levels in cells and tumors, and high relative to a non-specific 
control probe, DDAO palmitate. 
Apoptosis
In addition to using imaging techniques to noninvasively detect components of lipid 
metabolism, other biomarkers can be detected that offer information pertaining to non-
homeostatic states of cells and tissues in situ.  Apoptosis is often indicative of patient response to 
cancer therapy, accordingly, targeting markers of apoptosis can be useful to evaluate the efficacy 
of various interventions (251). Among these events are plasma membrane reorganization marked 
by PtdSer translocation to the outer leaflet of the membrane. PtdSer translocation can be detected 
using labeled ligands that bind anionic phospholipids, including proteins such as Annexin 5 or 
synaptotagmin (252) or organic molecules such as zinc dipicolylamine (253). A number of 
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labeling strategies have used this approach to create apoptosis sensors for optical (254), MR 
(255-257) and nuclear imaging when radiolabeled with 99Tc or 123I (258). Annexin has shown 
some promise as a molecular probe for this purpose though this strategy can be limited by 
suboptimal pharmacokinetics (259), and non-specific labeling of necrotic cells (260). 
Conclusion
Lipid metabolism is an essential component of cellular homeostasis that can become 
drastically altered during the process of malignant transformation. Most common driver 
mutations and oncogenes are related to growth cues and cellular stress responses, and many 
therapeutic strategies target these pathways such that the measurement of lipid metabolic 
changes can serve as a proxy for drug response pharmacodynamics. While MRS and PET 
approaches offer the ability to serially-measure lipid composition and flux, they are limited by 
spatial resolution. MSI and Optical Imaging, on the other hand, permit the appreciation of 
intratumoral heterogeneity but often require surgical exposure of the tissue site. Still, these 
approaches are finding increasing value in image-guided surgical resection and are experiencing 
fast-paced improvements in technology including the ability to image endogenous contrast, more 
specific probes that provide kinetic information, and sub-cellular resolution. For a balance 
between resolution and ability to image endogenous lipid signals without the need for new FDA-
approved contrast agents, MRS remains the gold standard for measuring lipid metabolic states in 
tumor and other tissues. New advances including two-dimensional MRS, hyperpolarized MR 
spectroscopic imaging, and higher field strength MRS continue to reshape our understanding of 
lipid metabolic changes during tumor growth and treatment response. This comes at a critical 
time as therapy continues to evolve with new signal transduction inhibitors, metabolic targeting 
agents, and immunotherapies change the landscape of cancer care.
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Figure Legends
Figure 1: Lipid metabolism pathways in the cell. Glucose transported into the cell is 
metabolized to pyruvate via the glycolytic pathway, and can be fed into the tricarboxylic acid 
(TCA) cycle for ATP production in the mitochondria. Citrate from the TCA cycle or from 
exogenous sources is converted to Acetyl-CoA in the cytoplasm and can be used for cholesterol 
or fatty acid (e.g. palmitate) biosynthesis. Cholesterol produced in this fashion can be used to 
synthesize membranes or be incorporated into sterols. Fatty acids can be desaturated or extended 
and then incorporated into triglycerides or incorporated into phospholipids via the Kennedy 
Pathway. Cholesterol and triglycerides fatty acids can also be taken up through specific transport 
mechanisms. The resulting lipid droplets, shown in the inset, contain fatty acids stored in 
phospholipid and fatty acid form that can be mobilized by phospholipases and lipases, 
respectively. Beta-oxidation (β-Ox) of free fatty acids from lipid droplets can be triggered to 
meet energy needs. In place of the third acyl group (Acyl3) attached to the glycerol moiety of 
triacylglycerides (orange oval), phospholipids have a phosphorylated polar head group (yellow 
sphere) that confers water solubility and creates organized bi-layer and micelle structures. 
Phospholipases can also elicit 2nd messenger signaling cascades by releasing bioactive fatty acids 
(e.g. sphingolipids, eicosanoids) and/or polar head groups in response to growth or stress cues. 
External cell signaling cues can also be transmitted by lipids in the case of isoprenylation and 
subsequent transport of small GTPases to dock with G protein-coupled receptors (GPCRs) on the 
cell surface.   
Figure 2: Major lipid metabolic pathways altered in cancer cells.  Metabolic 
reprogramming during malignant transformation mimics autonomous growth signaling in 
unicellular organisms. Common oncogenes in the PI3K/Akt/MTOR pathway, are often mutated 
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or upregulated due to their presence downstream of external growth factors and their ability to 
re-route cellular carbon sources toward fatty acid utilization as an energy source. Cancer cells 
can also supply the TCA cycle from glucose via aberrant glycolysis and from glutamine via IDH 
mutations, although the contributions of these pathways differ greatly depending on the energy 
needs of the cell. The transcription factor Myc promotes many malignant processes in cancer 
cells because it is a master regulator capable of triggering survival pathways in response to 
hypoxia and nutrient deprivation. Hypoxic conditions are a factor in many solid tumors and 
influence the local tumor microenvironment by dampening the immune response and activating 
hypoxia-inducible factor-1α (HIF1α), which among other things, initiates the regulatory function 
of sterol regulatory element binding protein 1 (SREBP-1) on fatty acid synthesis. Free fatty acids 
such as palmitate are used as energy sources or converted to bioactive eicosanoids to dampen the 
immune response and stabilize the ER stress that can result from saturated fatty acid 
accumulation.
Figure 3:  Changes in lipid metabolism in response to oncolytic viral treatment of Syrian 
hamster carcinomas. The oncolytic viral treatment induces coagulative necrosis, which is seen as 
hypo-intense areas within the tumor on T2-weighted MR image. In vivo MRS from the voxel 
(overlaid on the image) is shown on the right demonstrating resonances from unsaturated fatty 
acids, taurine and choline. Unlike the increased PUFA resonances observed during apoptosis 
(Figure 3), no No changes in PUFA resonances were observed in coagulative necrosis resulting 
from oncolytic viral treatment. Reprinted with permission from (138). 
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Figure 4. A) Confocal micrographs of SKOV3.ip cells treated for 48 h with cisplatin 
(CDDP) show increased lipid droplets as measured by Nile red staining, compared to untreated 
controls (CTRL). Fixed cells were counterstained with phalloidin 488 for actin (green) and DAPI 
for nuclei (blue). Scale bar represents 23.8 μm. (B) 1H NMR spectra of intact SKOV3.ip cells 
treated with 5 mM CDDP for 48 h (red) show increases in mobile lipids compared with untreated 
control cells (black). Labeled lipid resonances include: methine protons at 5.3 ppm (-CH=CH-); 
fatty chain methylene group at 1.3 ppm (-(CH2)n)- ; methyl group at 0.9 ppm (-CH3) ; and total 
choline (tCho) at 3.2 ppm (-N.(CH3)3). Reprinted with permission from (150). 
Figure 5: Increased lipids in response to choline kinase inhibition as an alternate therapy 
for the treatment of gliomas. In vivo MRS from an untreated F98 rat glioma (bottom spectrum) 
and after 5 days of treatment with a choline kinase inhibitor, MN58b (top spectrum). Increased 
mono-unsaturated lipid peaks (1.3 ppm) are evident with treatment. In addition, a significant 
increase in the poly-unsaturated fatty acids (PUFA, 2.8 ppm), indicating apoptotic cell death. As 
expected, a decrease in the total choline (tCho) peak was also observed in response to choline 
kinase inhibition. The MR image demonstrates placement of the voxel for MRS studies. 
Reprinted with permission from (114).
Figure 6: Single voxel 1H MR spectra from a GL261 tumor implanted into a mouse 
brain. Treatment with three cycles of temozolomide led to significant (*) increases in mobile 
lipid:Cre and tCho:Cre resonances at 28 days post inoculation (left) compared to spectra 
acquired before treatment (tight). Labeled resonances: Cho (choline: 3.2 ppm, Cre (creatine): 3.3 
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ppm, MLs (mobile lipid methylenes): 1.3 ppm, PUFAs: 2.8 ppm. Reprinted with permission 
from (128). 
Figure 7: Chemical structure of the common PET tracers used for detection of lipid 
metabolism. The radioactive isotope is denoted in red. 
Figure 8: MALDI-MSI images and corresponding H&E sections from human colorectal 
tumors (A-C) and adjacent tumor free regions (D-F). A selective projection of m/z 478.3 onto 
MALDI-MSI images reveals elevations in 1-palmitoyl-lysophosphatidylcholine in cancer-
containing areas compared to the non-tumor bearing tissue sections. Elevations in m/z 504.3, 
representing 1-oleoyl-lysophosphatidylcholine, were also observed in this study. Reprinted with 
permission from (203).   
Figure 9: In vivo NIR fluorescence imaging of phospholipase activity using the PC-PLC 
activatable probe Pyro-PL-BHQ in DU145 prostate tumor xenografts. Each mouse received 80 
nmol i.v. of (A) Pyro-PtdEtn, a permanently fluorescent analog used as a control, (B) Pyro-
PtdEtn-BHQ or (C) Pyro-PtdEtn-BHQ plus pre- and post- injections of the PC-PLC inhibitor 
D609. The fluorescence intensity from Pyro-PL-BHQ activation peaked at 6-7 h, and was 
inhibited by D609 treatment. Fluorescence persisted for up to 31 h in tumor tissue (T) excised 
from mice when compared to muscle (M) control. Reprinted with permission from (112).
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Abstract
Lipids represent a diverse array of molecules essential to the cell’s structure, defense, 
energy, and communication. Lipid metabolism can often become dysregulated during tumor 
development. During cancer therapy, targeted inhibition of cell proliferation can likewise cause 
widespread and drastic changes in lipid composition. Molecular imaging techniques have been 
developed to monitor altered lipid profiles as a biomarker for cancer diagnosis and treatment 
response. For decades, magnetic resonance spectroscopy has been the dominant noninvasive 
technique for studying lipid metabolite levels. Recent insights into the oncogenic transformations 
driving changes in lipid metabolism have revealed new mechanisms and signaling molecules that 
can be exploited using optical imaging, mass spectrometry imaging, and positron emission 
tomography. These novel imaging modalities have provided researchers a diverse toolbox to 
examine changes in lipids in response to a wide array of anticancer strategies including 
chemotherapy, radiation therapy, signal transduction inhibitors, gene therapy, immunotherapy or 
a combination of these strategies. The understanding of lipid metabolism in response to cancer 
therapy continues to evolve as each therapeutic method emerges, and this review seeks to 
summarize the current field and areas of unmet needs. 
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Abbreviations
18F-fluorodeoxyglucose (FDG)
2,5-dihydroxybenzoic acid (DHB) 
3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA)
acetyl-coenzyme A (acetyl-CoA) 
acute myeloid leukemia (AML) 
AMP-activated protein kinase (AMPK) 
ATP-citrate lyase (ACLY) 
beta-oxidation (β-Ox) 
black Hole Quencher (BHQ-3)
choline kinase (ChoK)
choline transporters (ChoTs)
cisplatin (CDDP)
7-hydroxy-9H-(1,3-dichloro-9,9-dimethylacridin-2-one  (DDAO)
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endoplasmic reticulum (ER) 
epidermal growth factor receptor (EGFR) 
fatty acid binding protein-4 (FABP-4)
G-protein coupled receptor (GPCR)
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hormone-sensitive lipase (HSL) 
hypoxia inducible factor (HIF) 
Indocyanine green (ICG) 
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mass spectrometry imaging (MSI)
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Introduction
Cancer cells exist in a hyperactive state of growth and use a complex network of lipid 
metabolic pathways to support this growing biomass. Lipids are a broad class of compounds that 
include fatty acids, triglycerides, steroids, phospholipids, and sphingolipids, among others. These 
molecules play critical roles in cellular compartmentalization, structural barriers, communication 
signals, energy storage, and homeostasis. Despite high vascularization, many cancer cells exist in 
regions of nutrient deprivation and tumors have adopted alternative strategies to maintain sources 
of lipid. In some cases the altered lipid metabolic state offers a therapeutic vulnerability, while in 
others, adaptations to intracellular lipid composition can be used by refractory tumors to resist 
therapies. Because these cancer-driven aberrations in lipid metabolism often contrast the 
surrounding tissue, there are several molecular imaging strategies that have been developed to 
monitor tumor margin, stage, and treatment response. 
I. Lipid Metabolism
A. Exogenous Lipid Uptake
De novo lipid synthesis pathways are crucial during embryogenesis and fetal 
development, but, after maturation, cells in most tissues are capable of acquiring sufficient 
circulating lipids to meet their biosynthetic and energetic needs (1-3). Cancer cells can access 
circulating lipids by overexpressing lipid-scavenging proteins. High exogenous lipids are 
associated with local invasive index, and obesity is also correlated with higher cancer incidence 
rates (4). Higher expression of low density lipoprotein (LDL) receptor has been found in 
transformed colorectal cells relative to normal cells (5). The LDL receptor in prostate cancer 
provides a major source of cellular cholesterol and essential fatty acids (6). Breast cancer and 
select sarcoma cells have been observed to secrete lipoprotein lipase (LPL) to release fatty acids 
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from triglycerides in circulating lipoproteins (7). Although macropinocytosis has been identified 
in cancer cells, little evidence exists to suggest that this is a relevant source of exogenous lipid in 
vivo (8). Instead, lipid binding proteins are thought to assist in the capture of lipids from the 
interstitial space and promote invasion (Figure 1), as overexpression of fatty acid binding 
protein-4 (FABP-4) has been observed on the surface of ovarian, prostate, bladder, and renal 
cancer cells (9,10). Fatty acid translocase, also known as CD36, is a long-chain fatty acid 
scavenger that contributes to high mammographic density in subjects at high-risk for breast 
cancer (11). Ovarian cancer cells can siphon free fatty acids from the lipid stores of the omentum 
by activating perilipin-A and hormone-sensitive lipase (HSL) in neighboring adipocytes (12). 
Studies have shown that removal of lipids from culture medium can trigger de novo lipid 
synthesis, emphasizing the dependency on lipids for cell proliferation and the adaptations cancer 
cells make to sustain their growing biomass (13).
B. De Novo Synthesis
Many cancers revert back to de novo lipid synthesis, and the lipogenic pathway is 
composed of many enzymes that are critical for tumor growth (14). Lipid synthesis starts at the 
energetic hub of the cell, the mitochondria, where acetyl-coenzyme A (acetyl-CoA) and 
oxaloacetate are condensed into citrate (Figure 1). Citrate from the TCA cycle can be shunted 
from the mitochondria and broken down by ATP-citrate lyase (ACLY) into acetyl-CoA. 
Cytosolic citrate can alternatively be sourced from the microenvironment by plasma membrane 
citrate transporter (PMCT)(Figure 1) (15). Besides feeding into the rate-limiting step of fatty acid 
synthesis, acetyl-CoA is also critical for histone acetylation and serves as a link between 
metabolic status and gene expression (16,17).
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Acetyl-CoA serves as the 2-carbon building block used for fatty acid synthesis. The 
enzyme FASN combines malonyl-CoA with repeated acetyl-CoA condensations to form 
palmitate. Palmitate is the saturated 16-carbon fatty acid from which most complex fatty acids in 
the body are derived (18). FASN overexpression is associated with poor prognosis in breast 
cancer (19) and FASN inhibitors derived from natural products (e.g. resveratrol) and synthetic 
molecules (e.g. orlistat) are being studied for their anti-neoplastic effects (20). Acetyl-CoA is 
also a synthetic precursor to 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) in the cholesterol 
biosynthesis pathway (Figure 1). Mevalonate is then produced by HMG-CoA reductase, the 
target of the lipid lowering drugs, the statins. The amplification of HMG-CoA reductase in many 
prostate tumors creates a growth dependency on cholesterol, and suggests a possible role for 
statins in treating these cancers (5,21). Mevalonate is also a precursor to farnesyl-diphosphate, 
which can further be processed to cholesterol, or used as a substrate for protein prenylation. 
Isoprenoids from the mevalonate cascade are critical for membrane anchoring and activation of 
the growth-related G-protein subunits Ras (farnesylated), Rho (geranylgeranylation), and many 
others (22) (Figure 1). 
Fatty acids can be chemically modified in many ways to meet the diverse range of 
specialized functions required for cellular function (Figure 1). Stearoyl-CoA desaturase-1 
(SCD1) produces mono-unsaturated fatty acids (MUFAs) from the saturated fatty acid chains 
sourced exogenously or from de novo synthesis. Saturated fatty acid accumulation in the 
endoplasmic reticulum (ER) triggers autophagy-induced apoptosis by activating the unfolded 
protein response (UPR) (23). By modulating MUFA to saturated fatty acid ratios intracellularly, 
SCD1 has a regulatory effect on cell survival and proliferation (24-26). The elongation-of-very-
long-chain-fatty acids (ELOVL) enzymes in the ER are responsible for polyunsaturated fatty 
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9
acid (PUFA) synthesis (27), as well as the conversion of saturated and monounsaturated fatty 
acids into the very long chain fatty acids (C > 18) that serve as building blocks of sphingolipids 
when combined with ceramide head groups (28). Free fatty acids are stored as triglycerides in 
lipid droplets or packed into the cell membrane as sphingolipids, cholesterol esters, or 
phospholipids. Lipid droplets in breast cancer cells have been found to increase with increasing 
malignancy and to be enriched in polyunsaturated fatty acids, especially arachidonic acid (29) 
Diacylglycerol (DAG) is an important lipid second messenger that also serves as a 
synthetic precursor for both membrane phospholipids and lipid droplet triacylglycerides (30-33). 
Major membrane phospholipids include phosphatidylcholine (PtdCho), 
phosphatidylethanolamine (PtdEtn), phosphatidylinositol (PtdIns), phosphatidylserine (PtdSer), 
among others, and vary in function, location, and relative abundance. The Kennedy pathway of 
phospholipid synthesis describes the addition of polar head-groups to the DAG backbone, and 
enzymes in this pathway are responsible for the accumulation of phosphocholine (PC) and 
phosphoethanolamine (PE) observed in many cancers (34). Choline uptake by choline 
transporters (ChoTs) and phosphorylation by choline kinase (ChoK) have, in particular, been 
consistently linked with increased invasiveness, drug resistance, and overall malignancy (35). 
C. Lipid Mobilization and Usage
Phospholipid and triacylglyceride levels are maintained by the concerted actions of 
catabolic enzymes that mobilize fatty acids from lipid droplets and cell membranes (36). Fatty 
acid release from lipid droplet storage involves lipases that can support aggressive cancer 
phenotypes in a manner similar to the pro-tumorigenic effects of exogenous fatty acids (37). 
Fatty acid release from membrane phospholipids is carried out by the phospholipase (PL) 
enzymes. PLA1 and PLA2 cleave phospholipids at the sn-1 and sn-2 positions, respectively. The 
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PLA2 family of enzymes are the primary producers of arachidonic acid and three major 
subgroups exist: calcium-dependent or cytosolic cPLA2, calcium-independent iPLA2, and 
secretory sPLA2 (38). While cPLA2 has a tumor-supportive role in many cancers, sPLA2 is 
thought to have tumor suppressive-functions (39). In contrast, iPLAs are housekeeping enzymes, 
primarily responsible for mobilizing lipids to maintain membrane integrity and general cellular 
energy metabolism during homeostasis. PLC cleaves phospholipids at the bond between glycerol 
and phosphate and contains pleckstrin homology domains for anchoring and cooperation with G-
protein coupled receptor (GPCR) signaling networks (40). When activated by growth factor 
receptors, PLD hydrolyzes the phospholipid head group (e.g. choline, ethanolamine, inositol, 
serine) to release PA and links growth factor signaling to cell proliferation (32).
Saturated free fatty acids can be broken down into acetyl-CoA to feed into the TCA 
cycle, and some cancers have been found to prefer fatty acid oxidation to pyruvate oxidation, 
even in sufficient glucose and oxygen environments (41). β-oxidation is an important energy 
pathway in prostate cancers, where glycolytic rates are low, and rapid citrate utilization requires 
a constant supply of acetyl-CoA (42). Peroxisome proliferator-activated receptor alpha (PPARα) 
is a transcription factor whose activation triggers breakdown of very long chain fatty acids in the 
peroxisomes, and fatty acid oxidation in the mitochondria. A complex network of interactions 
with PUFAs, namely arachidonic and linoleic acids, regulates PPARα activity (43). Aside from 
their direct signaling functions (44), arachidonic acid is an important substrates for 
cyclooxygenase, lipoxygenase, and cytochrome enzymes that catalyze the production of the 
eicosanoid family of bioactive lipids that have roles in innate immunity, inflammation, 
cardiovascular disease, and cancer (45,46). 
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II. Tumor Progression and Regression
A. Oncogenic Reprogramming
A common feature of cancer cells is the metabolic transition from oxidative 
phosphorylation to glycolysis, during which the rate of glucose consumption far exceeds the 
energy requirements of the cell (14). What initially appears to be wasteful energy utilization is in 
fact a method to feed glucose-derived pyruvate into biosynthesis, including fatty acids (Figure 
2). Glutamine has been identified in some cancers as an alternative energy source that can enter 
the TCA cycle (47) and provide a carbon source for citrate production (Figure 2), however the 
dependency on glutamine for anaplerosis varies considerably even among cancers of the same 
tissue (48,49). This may be due, in part, to heterogeneity in the local tissue microenvironment 
causing gradients in nutrients, oxygen and signaling factors that influence the energetic state of 
cells.
Under hypoxic conditions, solid tumors can become dependent on unsaturated fatty acid 
uptake from serum to prevent ER stress that can arise when rapid proliferation is unmet by 
nutrient availability (50). These exogenous fatty acids can arise from lipolysis in stromal cells in 
a manner comparable to cachexia (23). The recent resurgence of interest in cancer metabolism 
has improved our understanding of the adaptations tumor cells can make when fuel availability is 
variable. These adaptations are only possible because the common driving mutations in cancers 
often have direct involvement in metabolic pathways.
Many of the clinically prevalent oncogenes are capable of altering lipid uptake, 
production, or consumption to gain a competitive growth advantage (Figure 2). The transcription 
factor hypoxia inducible factor (HIF) is a downstream effector of Myc and is tightly regulated by 
the tumor suppressor gene p53. HIF induces FASN induction and lipid droplet formation for 
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energy storage to support the tumor microenvironment (18,51,52). FASN requires the reducing 
agent NADPH, which is produced from the pentose phosphate pathway that often becomes 
upregulated during cancer reprogramming (18). There is further evidence in renal cell carcinoma 
models that HIF2α-dependent lipid storage suppresses the ER stress response promoting tumor 
cell survival (53).  Glutamine uptake in glioma and acute myeloid leukemia (AML) is often 
accompanied or driven by isocitrate dehydrogenase-1 (IDH1) mutations that reroute glutamine 
toward citrate to provide fatty acid and cholesterol precursors independent of the TCA cycle 
(Figure 2) (54,55). In hypoxic environments where glucose metabolism is diverted to anaerobic 
lactate production, mutations in mitochondrial IDH2 provide a continued source of citrate for 
lipid synthesis, by allowing reductive carboxylation of glutamine-derived α-KG (56). The 
oncometabolite 2-hydroxyglutarate is produced by many cancer-specific IDH1 and IDH2 
mutations, and has widespread epigenetic effectors by altering DNA methylation (57-59).
AMP-activated protein kinase (AMPK) serves as an energetic sensor and master switch 
by inhibiting fatty acid synthesis in low energy states and stimulating consumption of fatty acids 
for energy in the mitochondria by β-oxidation (Figure 2). Sterol response element-binding 
proteins (SREBPs) (60) can activate transcription of genes involved in cholesterol and fatty acid 
synthesis and uptake, and are directly downstream of AMPK and the PI3K/Akt/MTOR signaling 
axis that includes many oncogenes (61). Epidermal growth factor receptor (EGFR) mutations are 
common tumor-driving factors that recruit phospholipases (62,63) and ChoKα (64) to the cell 
surface, leading to membrane remodeling and induction of mitogenic signals to drive cellular 
proliferation. Mitogenic growth signals can also come in the form of sterol-derived hormones 
(estrogens, progestogens, and androgens). Release of these sex hormones, their receptor 
expression, and the downstream signaling mediators are all common tumor-driving factors in 
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prostate, breast, endometrial and ovarian cancers (65). Farnesylation of Ras and 
geranylgeranylation of Rho GTPases are essential for downstream signaling through the 
phosphoinositol family of signaling lipids (66,67). Phosphoinositides (PI) comprise 10-20% of 
total cell phospholipids and among that fraction, phosphatidylinositol (4,5) phosphate-2 (PIP2) 
and phosphatidylinositol-4-phosphate constitute approximately 0.2-1% (68-70). This class of 
membrane lipids plays an integral role in proliferation, apoptosis, metabolism and migration, and 
is pivotal to transmembrane signal transduction because it regulates the distribution of receptor 
tyrosine kinases, G-protein-coupled receptors, and adhesion molecules among others (71).
Metabolic disease is a risk factor for many cancer types, promoting insulin resistance, 
hyperactive growth signals, and evasion of apoptosis that help set the conditions for malignant 
transformation (72). Histological tumor grade in the breast is clinically correlated with 
phosphomonoester (PME) accumulation (73), such as PC and PE, detectable by MR 
spectroscopy (74,75). PC promotes survival and mitogenic signaling through downstream 
cascades such as MAPK and Akt (73,76,77). PC can be formed through the actions of the 
enzyme choline kinase, or by phosphatidylcholine specific phospholipase C. Phospholipid 
catabolism can also be a source of other mitogenic second messengers such as DAG, PA, and 
lysophosphatidylcholine (LPC). DAG is released following the cleavage of phospholipids by 
PLC (78), activates protein kinase C (PKC) resulting in the release of intracellular calcium stores 
and subsequent Ca2+-dependent signaling. DAG and PC are also the synthetic precursors to the 
most abundant mammalian membrane phospholipid, PtdCho, whose levels are predictive of 
breast tumor grade, estrogen receptor status, and patient survival (79). It is intuitive to suspect 
that cancers in high adipose tissue use altered lipid metabolism to take advantage of the 
surrounding environment, however evidence of altered lipid metabolism in cancers that arise in 
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low-adipose tissues suggests that deranged lipid metabolism is a universal hallmark of cancer 
pathogenesis.
Variations in lipid composition are likely due to the heterogeneous nature of the tumor 
microenvironment, which is an ever-changing compartment of structural fibers, nutrients, 
cellular waste, and signaling molecules. Interstitial pH, extracellular matrix, bioactive lipids, and 
cytokines can alter the population and function of stromal cells and surrounding tissues. 
Extracellular lactate, the metabolic byproduct of aerobic glycolysis, is capable of transitioning 
tumor-associated macrophages from tumor-suppressive to tumor-supportive phenotypes (80,81). 
Biopsies of colon cancer specimens have been reported to contain high lipid deposition in 
regions of necrosis and infiltrating macrophages (82). These macrophages most likely resemble 
the immune-suppressive “alternatively-activated” phenotype, as classic (interferon gamma-
induced) activation does not enhance lipid phagocytosis in human myeloid populations (83). 
Alternatively-activated macrophages prefer fatty acid oxidation (84) and are thought to have 
critical roles in clearing/remodeling necrotic tissue, recruiting new blood vessels, and regulating 
innate and adaptive immunity (85). 
B. Lipid changes during Apoptosis/Necrosis
The role lipids play in nearly all cell survival pathways emphasizes their importance in 
tumor growth and invasion pathways, but lipid compartmentalization, metabolism, and signaling 
are also intricately involved in cell death pathways. During apoptosis, the release of 
lysophosphatidylcholine (LPC) and sphingosine-1-phosphate (S1P) by PLAs (86) and 
ceramidases (87) respectively, acts as a “find-me” signal to surrounding macrophages (88). Once 
recruited to the dying cell, exposed PtdSer on the apoptotic cell’s surface serves as the “eat me” 
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signal recognized by phagocytes (89). Unlike the organized compartmentalization of apoptotic 
cells into non-immunogenic apoptotic bodies, necrosis is characterized by the breakdown of the 
plasma membrane and release of the cellular contents that often triggers an immune reaction 
(90). Recently, lipid peroxidase networks have been identified as key mediators of cancer cell 
therapy resistance by reversing a non-apoptotic form of cell death known as ferroptosis can be 
induced by lipid peroxide accumulation (91).  Tumor cell response to therapy begins with 
activation of cell stress responses, which can ultimately decide the fate of the cell and 
surrounding tumor. 
Early changes in lipid metabolism have been reported in response to a wide range of 
cellular stresses (92), but lipid mobilization does not necessarily commit a cell to apoptosis (93). 
Many cells undergoing apoptosis produce lipid droplets, although there are exceptions (94), and 
fatty acids are first mobilized from membrane phospholipids by PLA2 activity (92,95). Reactive 
oxygen species (ROS) produced in the mitochondria of apoptotic cells are thought to inhibit the 
catalytically-active thiol groups on β-oxidation enzymes (96), thus free fatty acids are redirected 
into lipid droplets in the form of triglycerides and sterol esters (97,98). Lipid droplet formation in 
cancer may act as a drug reservoir to reduce intracellular concentrations of drug (99), or to 
absorb reactive oxygen species to protect further DNA damage (100). Lipogenesis of saturated 
fatty acids also makes the cell membrane less penetrable to drugs that enter by passive diffusion 
(101). Uptake of triglycerides by macrophages or neutrophils can dampen subsequent immune 
activation (102,103), providing another potential mechanism of immune escape. Ceramide 
accumulation regulates and can even trigger mitochondrial outer membrane permeability to fully 
commit a cell to apoptosis by allowing cytochrome C release to the cytosol (104). Other signs of 
cell stress that precede or arise during apoptosis are the rise in PUFA and glycerophosphocholine 
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(GPC) levels (105-107). These indicate a reprogramming of lipid metabolism and suggest that 
catabolic networks mobilize lipids from membrane phospholipids during this time. Many of 
these observations were first made using magnetic resonance spectroscopy (MRS) to non-
invasively measure lipid resonances of cancer cells undergoing stress responses and apoptosis 
(92).  
III. Imaging Metabolic Lipid Changes
The development of modern imaging techniques allows the detection of several key 
signaling pathways involved in lipid metabolism and its regulation/dysregulation in cancer. The 
ability to detect these pathways non-invasively aids in the discovery of potential targets for 
imaging or interventional therapies. In addition to developing probes to image lipids and 
alterations in lipid metabolism in mechanisms of oncogenesis, we can also image lipid-
dependent or –mediated signaling in response to therapy (108).  
A. Imaging lipids in tumors: MR Spectroscopy
MRS has been extensively employed for the study of biological material (from cell 
extracts, to homogenized tissue, and intact organisms) because it offers a non-invasive method to 
study the native distribution and dynamic nature of many relevant biomarkers of disease and 
therapeutic response. The search for disease-related metabolites requires the suppression of the 
overwhelming fat and water signals observed in proton MR spectra, however much can be 
learned from the diverse species that contribute to these lipid peaks. 
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B.  Choline and choline metabolites
MRS has been essential in the study of lipid metabolism and for the non-invasive 
observation of lipid metabolism in vitro and in vivo.  This is due to the ability to observe a 
number of lipid metabolites in 1H and 31P MR spectra on the basis of chemical shift 
discrimination. Due to the relative insensitivity of MR, observation is limited to soluble or MR-
visible metabolites in the high micromolar to millimolar levels. Lipid metabolites observable in 
31P MR spectra, include the PME, PC and PE and the PDE, GPC and GPE.  In 1H spectra, 
observable lipid metabolites include the total choline (tCho) resonance, a composite resonance 
encompassing free choline, PC and GPC. Thus there is overlap in the information available 
between 31P and 1H spectra, since the choline PC and GPC resonances seen in the 31P spectra are 
also observed in the tCho region of 1H spectra. The PME and PDE resonances report on 
pathways relevant to phospholipid metabolism. PC and PE are generally the anabolic products of 
choline kinase and ethanolamine kinases, although they can also be produced by the actions of 
phospholipase C.  The PDE resonances result from catabolism of phosphatidylcholine and 
phosphatidylethanolamine via the consecutive action of two phospholipases, A2 and 
lysophospholipase or A1.There are numerous excellent reviews on this topic (35,92,109,110), 
and the reader is referred to these for detailed information.  However, it is worth noting that 
consistent elevations in PMEs and tCho have been observed in a wide range of tumors including 
brain, prostate, lung, skin, ovarian and breast (111,112). As a means to monitor therapeutic 
response, tumor choline levels have been measured using MRS in animal (113-115) and human 
tumors (116-120) with mixed results, at least partly due to the technical difficulties associated 
with acquiring choline spectra on a background of high fat in normal breast tissue. The picture is 
further complicated because ChoK is not the only enzyme that contributes to PC accumulation, it 
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can be produced directly by the actions of PLC on PtdCho, or by the hydrolysis of GPC as a 
source of additional choline for subsequent phosphorylation.  Recent MRS applications have 
been used to detect changes in choline metabolism due to IDH mutations in glioma (59,121) 
explore the role of the glycerophosphodiesterase genes GDPD5 and GDPD6 on breast cancer 
cell migration/invasion (122) and profile metabolic changes in response to HIF1 and HIF2 
suppression (123).
C: Imaging lipids in tumors: MR-visible lipids
Proton MRS was originally used to detect MR-visible or mobile lipid signals in cultured 
cells and tumor biopsies. A series of resonances were observed arising from the fatty acryl chains 
in neutral lipids, triglyceride and cholesterol esters, including the terminal methyl groups, the 
methylenes in long chain fatty acids, and olefinic MUFA/PUFA resonances (124-127). MR 
detects only molecules that exist in a local environment with high rotational molecular motion 
and thus the observed signals arise predominantly from mobile or MR-visible lipids, composed 
of triglycerides and cholesterol esters sequestered in lipid droplets. In animal and human tumors, 
the observation of these lipid resonances require the use of short echo time spectroscopic pulse 
sequences due to the relatively short T2 relaxation times of mobile lipids. In vivo MRS studies 
initially used single voxel localization methods such as STEAM and PRESS for assessing the 
MRS pattern of lipids in tumors, due to the simplicity and accuracy of these methods. However, 
multi-voxel spectroscopic methods including chemical shift imaging are increasingly being used 
both in mouse glioma and xenograft models (128,129) as well as in human tumors (130) since 
these methods provide a better assessment of tumor heterogeneity. The presence of intense lipid 
signals from surrounding subcutaneous fat and muscle have been problematic in evaluating lipid 
signals by MRS methods, thus outer volume fat suppression sequences become critical. For this 
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reason, the majority of studies on intra-tumoral lipids have been focused on the brain where 
subcutaneous fat is at a minimum. However, useful insights into human tumor composition have 
still been made in other tumors, despite the problems associated with high fat content in 
peripheral tissue. 
The presence of lipids in human tumors was initially reported by Kuesel et al. (124) 
where a correlation between MR-visible lipids, tumor malignancy and necrosis was observed in 
brain tumors. These initial findings were subsequently confirmed in in vivo imaging studies as 
well as in histologically different brain tumor types (131). An early demonstration of the 
sensitivity of lipid signals for accurate diagnosis of supra-tentorial brain tumors was 
demonstrated by Preul et al. (132) suggesting lipid signals as a potential biomarker for grading of 
astrocytomas. Correlation of lipids with malignancy was also reported in pediatric brain tumors 
(133) and a further study in pediatric brain tumors suggested the presence of lipids as a marker of 
poor survival (134). Taken together, the presence of MR-visible lipid signals seems to be a 
marker for malignancy and poor prognosis. In our recent review on the role of lipids in tumors 
(92) we argued that increased MR-visible lipids in tumors are indicative of a stress response and 
that their localization reflects areas of cellular hypoxia and or necrosis.
MRS methods have been used to assess changes in the metabolic profile of tumors as 
markers of early therapeutic response. Most xenograft and clinical studies have focused on 
evaluating reductions in the total choline or lactate signal as a marker of treatment response 
Changes in lipid signals not only suggest a positive response, but increases in PUFA, a putative 
marker of apoptosis (106), may also aid in understanding the mechanism of cell death induced by 
specific treatments.
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Gene therapy induced changes in lipids
One of the first studies to implement MRS to evaluate changes in metabolism during 
gene therapy reported a progressive increase in the lipid resonance at 1.3 ppm in 9L rat tumors 
that were injected intratumorally with adenoviral HSV-to followed by ganciclovir treatment 
(135). These initial studies were followed by several studies of the HSV-tk positive BT4C 
glioma model treated with ganciclovir (106,129,136), which established accumulation of PUFA 
resonances as a marker of treatment induced apoptosis. The PUFA resonances arise from 
phospholipase A2 activity leading to hydrolysis of phospholipids in the cell membrane (137). 
These studies indicate that early increases in mobile lipid resonances after therapeutic 
intervention may be suggestive of apoptosis and positive treatment response. The temporal 
evolution of these resonances may be variable, with a decrease in lipid resonances during 
formation of scar tissue after cell death and lysis. However, the mode and nature of therapeutic 
interventions could affect changes in lipid resonances. A recent study involving oncolytic viral 
treatment of immunocompetent Syrian hamster carcinomas as well as a patient with 
neuroblastoma reported lower unsaturated fatty acids, as measured from the olefinic resonance at 
5.3 ppm (Figure 3) in responding tumors than in non-responding tumors (138), which appears to 
be an exception to the norm. Unlike previous studies, which resulted in an apoptotic tumor cell 
death after treatment, treatment with oncolytic viruses resulted in multifocal necrosis and a 
substantial cellular inflammatory response. Taken together, these studies indicate that changes in 
PUFA resonances could possibly be used to differentiate apoptosis from necrosis, although 
further data is needed to substantiate this finding. 
A decreased PUFA resonance, in comparison to normal breast tissue, was reported in a 
patient with breast cancer using selective multiple quantum coherence spectroscopy (139). In 
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contrast to most tumors, a decrease in total tumor lipids was observed in pancreatic cancer 
compared to pancreatitis as evaluated by MR studies of patient biopsy samples (140) as well as 
in vivo comparing focal pancreatitis to pancreatic adenocarcinoma (141). Although the exact 
reason for this apparent anomaly is unclear, the pancreatic tumor microenvironment includes 
stromal tissue that comprises up to 80% of the tumor mass (142). Thus, it is possible that the 
dominant factor contributing to the MR visible lipid signal in pancreatic cancer arises from the 
dynamic assortment of extracellular matrix components, infiltrating immune cells, macrophages, 
pancreatic stellate cells, vascular cells, fibroblasts and myofibroblasts.  
Chemotherapy induced changes in lipids
There have been several MRS studies describing alterations in lipid levels in response to 
treatment with cytotoxic agents. Increased triglyceride resonances were observed in the 
malignant MDA-MB-435 breast cancer cell line treated with the anti-inflammatory agent 
indomethacin (143), a drug that has been shown to reduce tumor invasion and inhibit metastasis. 
Similar increases have also been observed in cells treated with antimitochondrial agents and 
other cytotoxic drugs (96,144-148). Treatment of DU145 prostate cancer cells with the 
differentiating agents phenylacetate or phenylbutyrate also led to a time dependent increase in 
lipid signals, accompanied by increased in GPC, indicating cell stress that precedes the induction 
of apoptosis (107,147). Increased apoptosis in BT4C glioma cells after exposure to cisplatin 
resulted in increases in both saturated fatty acids and PUFA resonances (149). Treatment with 
subcytotoxic doses of cisplatin induced similar increases in saturated and total unsaturated fatty 
acid (5.3 ppm) resonances in HER2+ ovarian cancer cells (150) (Figure 4).  Exposure of the 
VEGFR tyrosine kinase inhibitor SU1498 on human U87 glioma cells induced a significant 
increase in lipids with a concomitant decrease in GPC (151). Although cell studies point towards 
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an increase in MR-visible lipid signals in tumors as a marker of response to chemotherapy, 
translation of these findings to in vivo settings have been challenging due to the confounding 
presence of lipid signals from hypoxic/necrotic regions in the tumor or contamination from lipid 
signals outside the tumor. 
Many factors influence in vivo MRS and make it difficult to predict whether it will 
provide useful biomarkers for new therapeutic interventions. For example, the PI3K/mTOR 
inhibitor voxtali in the presence or absence of temozolomide directly alters the phosphorylation 
of the phospholipid PtdIns in glioblastoma tumors, but causes no detectable changes in 1H MR 
spectra, even though hyperpolarized 13C MRS showed reduced conversion of pyruvate to lactate 
(152). Nevertheless, many studies have successfully evaluated changes in lipid signals in 
response to chemotherapy in tumor xenografts. The efficacy of etoposide, a topoisomerase 
inhibitor, was tested on a murine lymphoma model and a significant increase in the 1.3 ppm 
methylene mobile lipid resonance was noted following etoposide-induced apoptosis (153). 
Treatment of F98 rat gliomas with the choline kinase inhibitor MN58b resulted in a significant 
increase in both saturated (1.3 ppm) and polyunsaturated (2.8 ppm) fatty acids (Figure 5) that 
correlated with increased treatment-induced apoptosis (114). Similar increases in saturated and 
polyunsaturated lipid resonances were observed in GL261 glioma tumors in mice treated with 
temozolomide (128) (Figure 6).  In contrast, treatment of C6, RG2, and GL261 glioma models 
with the nitrones, PBN (α-phenyl-tert-butylnitrone) and OKN007 (2,4-disulfophenyl-PBN) 
resulted in a decrease in lipid resonances after treatment, which was attributed to a decrease in 
necrosis and normalization of the metabolic profile rather than the increase in apoptosis 
generally reported in tumor treatment studies (154). Increases in neutral lipid resonances were 
also correlated with tumor growth arrest and treatment response in a mouse model of HER2+ 
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ovarian cancer treated with cisplatin (150). No changes in total choline were noted in this study, 
as the authors found changes in neutral lipids to be a more sensitive marker of treatment 
response.
Radiation therapy induced changes in lipids
Radiation therapy is one of the most commonly used therapeutic strategies for solid 
tumors in the clinic. Although several studies point towards increased lipid resonances in 
radiation-induced necrosis, relatively few studies have evaluated changes in lipid resonances as a 
marker of early response to radiation therapy. Cervical cancer biopsy samples obtained from 
patients treated with radiation therapy were studied by HR-MAS, which revealed a direct 
correlation between the degree of apoptosis and lipid resonances (155) confirming the 
observations made in cell and xenograft studies. A xenograft model of non-Hodgkin’s diffuse 
large B cell lymphoma treated with radiation th rapy demonstrated a significant increase in both 
mono and unsaturated lipid resonances within 3 days of treatment (156). The increase in lipid 
resonances corresponded with histology findings of increased apoptosis and oil red O staining, 
supporting the idea that unsaturated (PUFA) lipid accumulation is a marker of therapy induced 
apoptosis. 
D. Positron Emission Tomography
Positron emission tomography (PET) measures the gamma rays produced when an 
electron collides with a positron emitted from a beta-decaying nucleus. PET scans require the 
administration of a radioactive substrate, but the high sensitivity of PET means that only tracer 
levels of radiolabeled material are needed. For tumor imaging, 18F-fluorodeoxyglucose (FDG) is 
by far the most commonly employed PET tracer (Figure 7). FDG exploits the enhanced aerobic 
glycolysis observed in many tumors, a phenomenon known as the Warburg effect. 
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Overexpression of plasma membrane glucose transporters and hexokinase activity rapidly 
internalize FDG and phosphorylate it in the first step of glycolysis. This reaction traps FDG-6-P 
in the cell, but the substrate is unable to be metabolized further. FDG-PET is widely used 
clinically for the staging of primary tumors, but because of the ability of PET to perform a full-
body scan, it is also important for the detection of metastases. FDG-PET can also be used to 
monitor tumor regression post-therapy, and has been used in several instances to monitor FASN 
inhibitor therapies due to the link between glycolysis and fatty acid synthesis (157,158). One 
caveat is that it is difficult to assess enhanced FDG tumor uptake in tissues with high glucose 
utilization (e.g. brain and heart) or in organs of excretion (e.g. kidney and bladder). There is also 
the potential for background labeling in metabolically active cells, such as lymphocytes in sites 
of inflammation. Furthermore, some tumors, such as the prostate, are not FDG avid and have 
relatively low uptake.
A promising alternative to FDG for tumor lipid imaging is 18F or 11C labeled choline 
(Figure 7). This strategy relies on the upregulation of choline transporters and ChoK in tumor 
cells. The concerted action of these components achieves tumor tissue contrast by rapidly 
internalizing and phosphorylating the choline mimetic radioligands. Choline PET is becoming 
more widely used for tumor detection, especially in the prostate (159) but also in other tumors 
such as gliomas (160). Choline PET has also been used to track tumor recurrence, metastasis, 
and response to chemo and radiotherapy (161-164). One challenge facing choline PET is the 
discrepancy between labeled choline tracer uptake and steady state metabolites observed using 
MRS (165). This could be due to intrinsic differences between choline transport and 
phosphorylation that manifest as differences in tracer uptake relative to steady-state levels, but it 
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could also be due to alternative pathways such as metabolism of the choline tracers in other 
organs such as liver (166).
The low FDG avidity of prostate tumors is linked to their metabolic preference for β-
oxidation of fatty acids, rather than glutaminolysis or glucose metabolism, as a primary energy 
source (42). A variety of 18F-labeled fatty acid analogs have been synthesized (Figure 7), and the 
metabolism of these probes effectively trap the radiolabel specifically in cells with high usage of 
β-oxidation (167,168). In metabolizable probes, labeling at the hydrophobic end of the molecule 
allows these probes to be consumed through β-oxidation. In non-metabolizable probes, chemical 
modifications are nearer to the carboxyl group, which still allows cell uptake and potential 
incorporation into phospholipids or triglycerides, but further oxidative metabolism is prevented 
(169). Labeled fatty acid probes, such as BMIPP (Figure 7), have been primarily employed to 
monitor metabolism in tissues with high levels of β-oxidation, mostly cardiac and to a lesser 
extent skeletal muscle (170-176). Use of these probes to study cancer has been limited, even 
though the use of β-oxidation as a potential cancer energy source has been known for decades 
(177,178).  
Although the half-life of 11C is quite short (20 min), it is still possible to observe 11C 
palmitate uptake and distinguish storage in triglycerides vs metabolism by β-oxidation (179,180). 
Regions of high fatty acid synthesis have been imaged using 11C-acetate incorporation into 
palmitate (181), although the intermediate acetyl-CoA has other potential metabolic fates such as 
the Krebs cycle or histone modification. For this reason, 11C-acetate has been used to monitor 
prostate tumors during therapy and recurrent lesions, but is incapable of distinguishing malignant 
tumors from benign hyperplastic nodules (182-185). Several radiolabeled ether lipids containing 
PC moieties (186) have been made (Figure 7) based upon early observations of elevated 
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phospholipid-ethers in neoplastic tissue (187,188). Due to the preferential accumulation and 
retention of these alkylphosphonium analogs, 124I-CLR1404 was developed and recently tested in 
brain tumor PET imaging where a tumor/normal brain signal ratio of 30 was reported (189). 
Replacement of the PET isotope with the radio-ablative 131I-CLR1404 agent improved survival 
in tumor-bearing rodents and provided a novel theranostic platform wherein 124I can assist in the 
planning of 131I therapy.
E. Mass Spectrometry Imaging
Mass spectrometry imaging (MSI) is a powerful modality for the detailed spatial 
detection of protein, metabolite and drug distribution in tissues. MSI consists of a family of 
techniques that includes matrix-assisted laser desorption ionization (MALDI) MSI, secondary 
ion mass spectrometry (SIMS), matrix electrospray-MSI (ES-MSI), and nanostructure-initiator 
mass spectrometry (NIMS). For the detection of lipids, the most commonly used technique is 
MALDI MSI (190), which has a large range of applications and provides a good overall 
combination of spatial resolution, intact molecule sensitivity and probing depth (190). MALDI 
provides a critical platform for the spatial detection of lipids and lipid metabolites, as there is a 
lack of suitable reagents and antibodies for the analysis of tissue lipids in situ (191). 
MSI techniques are invasive procedures, requiring the preparation and embedding of a 
thin tissue slice followed by rasterized destruction by laser or primary ion beams. For MALDI, 
tissue is embedded in a matrix such as gelatin and α-cyano-4-hydroxycinnamic acid (CHCA) or 
2,5-dihydroxybenzoic acid (DHB) (192). Washing the tissues with aqueous solutions of 
ammonium formate or phospholipases prior to embedding can be used to enhance certain lipid 
species and improve signal to noise (191). MSI can detect hundreds of molecules in a single 
sample with a routine spatial resolution of 50−100 μm, and a small molecule resolution as high 
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as 5−10 μm (193). Because matrix deposition is a slow process and the application of a wet 
matrix to tissue can cause metabolite shift, matrix-free techniques using nanoparticle initiators 
have been developed and these often provide simpler spectra to interpret (194,195). These NIMS 
procedures provide comparable lipid profiles, but with improved spatial resolution (196).
MSI has been used extensively to study lipid in primary human tumor tissue as well as 
tumor cell lines and xenografts. In human tissues, a consistent observation of elevated 
phospholipids has been observed in cancer compared to normal tissues. This includes breast 
tumors and invasive ductal carcinomas compared to carcinoma in situ (197-199), gastric cancers 
(200), renal cell carcinomas (201), human lung squamous cell carcinoma (202) and colorectal 
carcinoma (203,204). The most frequent observation is of increased PtdCho in tumors, but 
increases in PtdEtn, PtdIns, and PA hav  also been observed (199,205,206). Some studies have 
demonstrated increases in ether-linked lipids (199). Lyso-phospholipids have been reported to 
increase in colorectal tumors, but decrease in gastric and prostate cancers (200,203,207) (Figure 
8). Fatty acid levels have also been observed to increase in a number of tumors (199), but it is 
uncertain whether these are free fatty acids or acyl components of more complex lipids. 
Studies in tumor xenografts have confirmed the general observations of increased 
phospholipids and ether-linked lipids in tumor tissues. Measurement of choline metabolites in 
breast cancer xenografts using MR spectroscopic imaging combined with MALDI-MSI revealed 
differences in spatial distribution with PC and choline levels concentrated in normoxic tumor 
regions (208). When correlated with the expression of a hypoxia-response element, PtdCho 
elevation was concentrated in hypoxic regions whereas LPC was elevated in necrotic regions 
(192,209). Further studies have indicated distinct microenvironmental lipid distribution with 
higher levels of ether-linked PtdEtn in viable tumor and ether-linked PtdCho in necrotic regions 
Page 86 of 128
http://mc.manuscriptcentral.com/nbm
NMR in Biomedicine - For Peer Review Only
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Peer Review Only
28
(193). Elongated fatty acyl chain length in phospholipids of human lung squamous cell 
carcinomas was reproduced in mouse xenografts and correlated with the expression of the acyl 
chain elongase ELOVL6 (210). These data demonstrate the role of MSI in identifying distinct 
tumor microenvironments by their molecular signatures.  
While MSI has revealed a number of potential lipid-related cancer markers, there are very 
few studies that have employed MSI lipids to monitor cancer treatment. One recent study has 
identified transient decreases in serum PtdCho and lyso-PtdCho associated with response to 
radiation in head and neck tumor patients (211). A second study has indicated that LPC (16:0) is 
a significant predictor of PSA recurrence in human prostate cancer patients (207). The NIMS 
technique is capable of simultaneous monitoring of drug accumulation and endogenous water-
soluble metabolite distribution (212,213). Adopting this technique to study drugs that target lipid 
metabolism in tumors should be a priority in this field. These data indicate that further 
investigation into the utility of lipid biomarkers to assess treatment response is warranted. 
F. Optical Imaging 
Optical imaging is a cost-effective and relatively easy-to-use imaging modality that 
makes it a valuable tool for non-invasive longitudinal imaging. The range of detectable 
wavelengths is broad enough to allow multiplex imaging, and these principles have been applied 
to a number of medical diagnostic platforms, including flow cytometry, fluorescence 
microscopy, and diffuse optical imaging. In vivo, optical imaging is limited by attenuated light 
penetration through tissue due to scattering and absorption in the visible wavelengths. This is 
partially alleviated by using chromophores that absorb or emit in the near infrared region (675 – 
900 nm) where absorption by hemoglobin, deoxyhemoglobin and water is at a minimum. In 
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addition, several endogenous proteins, such as laminin and elastin, autofluoresce and elevate the 
background signal during in vivo measurements. As a result, the observable depths of optical 
imaging are usually limited to 1 cm or less. Thus in vivo optical imaging has predominantly 
focused on single-channel fluorescence or bioluminescence on a macro level (< 15x 
magnification) in mice or other small animals. Bioluminescence is not practical in clinical 
settings, because it requires transfection with an invertebrate luminescent protein, but it is a 
highly sensitive reporter that, in the field of lipid metabolism, has been adapted to map regions of 
heightened fatty acid uptake (214). Advances in CCD sensitivity has recently sparked renewed 
interest in Cerenkov radiation as an additional source of emitted light that can be detected in vivo 
(215,216). This signal may one day offer functional information concordant with the 
tomographical information provided by PET (217). 
New optical imaging technologies in oncology have largely followed advancements in 
vascular imaging. Before diffuse optical tomography became a subject of interest in 
mammographic screening, the observation was made that absorption of circulating hemoglobin 
changes in an oxygen-dependent manner (218). This was a pioneering study in translational 
optical imaging, but 20 years later routine clinical optical imaging remains limited outside of 
optical coherence tomography (OCT) in ophthalmic applications (219-221). OCT uses a rastered 
application of NIR light and interferometry to produce a 3-D scanning image of the retina. The 
use of NIR wavelengths still limits the application to surface phenomena, less than 1 cm deep in 
the tissue. OCT has also been employed in oncology, most notably to detect the development of 
esophageal tumors (222,223), With regards to lipids, OCT is most commonly used for 
atherosclerotic plaque detection in cadavers and patients, which is based upon its sensitivity to 
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lipid deposits in local vascular sites (224,225). This leads to the possibility for future applications 
of OCT as a method to distinguish lipid levels in treated tumor tissue. 
In small animal optical imaging, enhanced contrast is often provided by the 
administration of exogenous NIR fluorescent compounds. There are a growing number of these 
molecular probes that allow for noninvasive optical imaging of lipid metabolism pathways. The 
probes are generally of three types: passive molecules that are used as blood pool agents and rely 
on leaky vasculature to accumulate at the site of pathology, targeted permanently fluorescent 
molecules that can be taken up selectively as substrates or inhibitors of lipid metabolic pathways, 
and smart quenched fluorescent molecules that can be selectively activated by enzymes. 
Fluorescence imaging using these probes allows for specific and localized detection of metabolic 
activity.  
Indocyanine green (ICG) is a clinically approved blood-pooling agent that has been used 
for tumor detection. Collection of ICG in solid tumors has been attributed to the enhanced 
permeability and retention caused by disordered vasculature and insufficient lymphatic systems 
in tumors (226), however tumor-associated macrophages in lipid-rich regions may have an 
underappreciated role in this phenomenon. In atherosclerotic plaques, ICG has been observed to 
accumulate preferentially in the lipid-rich macrophages in both rabbits and patients (227). MRI, 
PET, and optical imaging of tumor-associated macrophages have been described extensively 
(228-230) and these methods should be used to explore co-localization of lipid profiles with 
immune infiltration in the tumor setting. 
Lipid uptake and synthesis
Lipid uptake and synthesis are essential to the maintenance of mammalian cell 
membranes. For this reason, a constant source of precursors are required to maintain the 
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proliferative nature of the cancer cell. Tumor cells synthesize and accumulate membrane lipids, 
such as PtdCho, at a rate that greatly outpaces the surrounding normal tissue, and this offers an 
avenue that can be exploited for selective delivery of imaging and therapeutic agents. The 
introduction of fluorescently labeled lipid analogs into the tumor microenvironment can also be 
used to visualize lipid scavenger activity. Direct fluorescent labeling of PtdCho has been 
reported using visible fluorophores, so high background in normal tissues is a general feature of 
these approaches (231). A common approach is to employ fatty acid probes to which non-polar 
dyes such as BODIPY have been attached (232). Depending on the metabolic state of the cell, 
these lipid analogs can be incorporated into phospholipids or neutral lipids in lipid droplets. The 
alkylphosphocholine analogs described for PET imaging have also been adapted with BODIPY 
or heptamethine dyes for imaging of tumor margins and draining lymph nodes (233). 
Choline kinase
Choline kinase catalyzes the conversion of choline to PC, and is elevated in several types 
of cancers. Its upregulation has been correlated with the transition of normal breast epithelium 
toward a malignant phenotype, and selective inhibitors have been developed for Phase I clinical 
trials in solid tumors (ClinicalTrials.gov, NCT01215864). Based on these studies, we developed 
a series of fluorescent inhibitors that selectively bind ChoK and emit fluorescence in the near 
infrared optical window (234). The design exploited the structural similarities between ChoK 
inhibitors and cyanine dyes frequently employed for optical imaging, and did not rely on dye 
conjugation to existing inhibitor structures (235). The probe, JAS239, showed elevated uptake in 
tumors that overexpressed ChoK, and more importantly, had reduced uptake in tumors after 
chemotherapy (236).
Phosphatidylinositol signaling pathway
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Many oncogenic signaling pathways are mediated by PtdIns, which makes these lipids 
attractive targets for cancer imaging probes. In order to interrogate the role of these 
phospholipids on cell signaling, Yoon et al. engineered a fluorescent PIP2 sensor to study its role 
in membrane remodeling, regulation of membrane proteins, and regulation of the cytoskeleton  
(236-238). This probe was engineered with the visible fluorophore (2-dimethyl-amino-6-acyl-
naphthaline) optimized for its lipophilic properties, limiting its utility for detection of lipid 
dynamics in vivo. Because IP3 and DAG mediate the release of intracellular calcium and are 
activated by lipid metabolic pathways, optical probes based upon flu-4 or BAPTA can provide 
an indirect means of assessing these bioactive lipids (239-241). DAG can be evaluated directly 
using radiolabeling (242) or using optical techniques such as FRET to detect activated DAG 
intercalation in the plasma membrane (243).  
Phospholipases 
Phospholipases are catabolic enzymes that can be targeted with lipid based quenched 
optical probes that are activated by enzymatic hydrolysis (39). Upregulation of cPLA2 has been 
observed in breast and prostate cancers (112), and elevated levels of PC and 
phosphoethanolamine have been attributed to PLC activation in breast cancer, ovarian cancer 
and melanoma (109). Activatable probes with phospholipid-based structures, a linker that 
regulates enzyme accessibility, a quenchable fluorophore or light-emitting compound, and a 
cleavable quenching domain have been designed as fluorescent agents for quantifying 
phospholipase activity. The advantage of this approach is the enhanced signal to noise available 
from the continuous enzymatic release of fluorescent substrates. Enzyme activated BODIPY 
probes have been employed to examine phospholipase activity in many systems including the 
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digestive physiology of the zebra fish (244-247). While useful for cells, small transparent 
animals and intravital microscopy, the optical properties of BODIPY limit its detection in tissue. 
There are several quenched fluorophores commercially available with emission in the visible 
range. In the NIR range, we developed analogous probes targeting PLA2 and PLC for in vivo 
applications (248). These self-quenching probes were composed of pyropheophorbide-a (Pyro) 
tethered to PtdEtn and a Black Hole Quencher (BHQ-3). While Pyro has an excitation maximum 
excitable Soret band at 418 nm that emits at 660 nm, its absorption peak at 670 with emission at 
725 nm makes it suitable for in vivo imaging. The specificity of these probes to various 
phospholipase isoforms could be modulated by altering the spacer length between Pyro and the 
glycerol backbone. The resulting construct, Pyro-PtdEtn-BHQ, was highly specific to PtdCho-
specific PLC (PC-PLC) both in vitro and in vivo and we used this to detected upregulation and 
activation of this enzyme in DU145 prostate cancer xenografts (Figure 9) (112).  
Arachidonic acid, a PUFA found in the sn-2 position of phospholipids, is mobilized by 
the activity of cytosolic or cPLA2 acting on membrane-associated phospholipids.  The redox 
activity of COX-2 catalyzes the conversion of arachidonic acid to prostaglandins that act as a 
lipid second messenger.  Arachidonic acid is first converted to prostaglandin G2, and then the 
peroxidase activity of COX-2 converts it to the unstable H2 isoform that is converted to one of 
several homologous tissue- and function-specific isoforms of prostaglandins.  It is prostaglandin 
E2 that is notably upregulated in several types of cancer contributing to aberrant signaling (249). 
In order to utilize this signal transduction pathway to image pathogenic events, there are several 
points of interrogation possible: using activatable probes to evaluate COX-2 activity, directly 
measure PGE2 levels with targeted probes, or evaluate activation of further downstream events.  
Page 92 of 128
http://mc.manuscriptcentral.com/nbm
NMR in Biomedicine - For Peer Review Only
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Peer Review Only
34
Detection of cPLA2 using a cleavable construct requires a probe that contains 
arachidonic acid, to account for the specificity of the enzyme for this fatty acid, as well as a 
small enough head group to fit into the active site.  Previous studies had shown that arachidonic 
acid esterified to visible fluorophores such as 7-hydroxycoumarin were highly specific for 
cPLA2 and displayed similar hydrolysis kinetics to native substrates (250). We adapted this 
caged fluorescence protocol using fluorophores that emit in the red wavelength range (660-680 
nm) to create cPLA2 sensitive probes suitable for in vivo imaging. Probe selectivity could be 
modulated by choice of fatty acids and fluorophores, with DDAO arachidonate performing the 
best in vitro, in cells and tumors. Here, arachidonic acid provided the optimum fatty acid 
substrate for cPLA2 and DDAO (7-hydroxy-9H-(1,3-dichloro-9,9-dimethylacridin-2-one) was 
the most resistant to non-specific aqueous hydrolysis. Probe activation was shown to be 
proportional to cPLA2 expression levels in cells and tumors, and high relative to a non-specific 
control probe, DDAO palmitate. 
Apoptosis
In addition to using imaging techniques to noninvasively detect components of lipid 
metabolism, other biomarkers can be detected that offer information pertaining to non-
homeostatic states of cells and tissues in situ.  Apoptosis is often indicative of patient response to 
cancer therapy, accordingly, targeting markers of apoptosis can be useful to evaluate the efficacy 
of various interventions (251). Among these events are plasma membrane reorganization marked 
by PtdSer translocation to the outer leaflet of the membrane. PtdSer translocation can be detected 
using labeled ligands that bind anionic phospholipids, including proteins such as Annexin 5 or 
synaptotagmin (252) or organic molecules such as zinc dipicolylamine (253). A number of 
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labeling strategies have used this approach to create apoptosis sensors for optical (254), MR 
(255-257) and nuclear imaging when radiolabeled with 99Tc or 123I (258). Annexin has shown 
some promise as a molecular probe for this purpose though this strategy can be limited by 
suboptimal pharmacokinetics (259), and non-specific labeling of necrotic cells (260). 
Conclusion
Lipid metabolism is an essential component of cellular homeostasis that can become 
drastically altered during the process of malignant transformation. Most common driver 
mutations and oncogenes are related to growth cues and cellular stress responses, and many 
therapeutic strategies target these pathways such that the measurement of lipid metabolic 
changes can serve as a proxy for drug response pharmacodynamics. While MRS and PET 
approaches offer the ability to serially-measure lipid composition and flux, they are limited by 
spatial resolution. MSI and Optical Imaging, on the other hand, permit the appreciation of 
intratumoral heterogeneity but often require surgical exposure of the tissue site. Still, these 
approaches are finding increasing value in image-guided surgical resection and are experiencing 
fast-paced improvements in technology including the ability to image endogenous contrast, more 
specific probes that provide kinetic information, and sub-cellular resolution. For a balance 
between resolution and ability to image endogenous lipid signals without the need for new FDA-
approved contrast agents, MRS remains the gold standard for measuring lipid metabolic states in 
tumor and other tissues. New advances including two-dimensional MRS, hyperpolarized MR 
spectroscopic imaging, and higher field strength MRS continue to reshape our understanding of 
lipid metabolic changes during tumor growth and treatment response. This comes at a critical 
time as therapy continues to evolve with new signal transduction inhibitors, metabolic targeting 
agents, and immunotherapies change the landscape of cancer care.
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Figure Legends
Figure 1: Lipid metabolism pathways in the cell. Glucose transported into the cell is 
metabolized to pyruvate via the glycolytic pathway, and can be fed into the tricarboxylic acid 
(TCA) cycle for ATP production in the mitochondria. Citrate from the TCA cycle or from 
exogenous sources is converted to Acetyl-CoA in the cytoplasm and can be used for cholesterol 
or fatty acid (e.g. palmitate) biosynthesis. Cholesterol produced in this fashion can be used to 
synthesize membranes or be incorporated into sterols. Fatty acids can be desaturated or extended 
and then incorporated into triglycerides or incorporated into phospholipids via the Kennedy 
Pathway. Cholesterol and triglycerides fatty acids can also be taken up through specific transport 
mechanisms. The resulting lipid droplets, shown in the inset, contain fatty acids stored in 
phospholipid and fatty acid form that can be mobilized by phospholipases and lipases, 
respectively. Beta-oxidation (β-Ox) of free fatty acids from lipid droplets can be triggered to 
meet energy needs. In place of the third acyl group (Acyl3) attached to the glycerol moiety of 
triacylglycerides (orange oval), phospholipids have a phosphorylated polar head group (yellow 
sphere) that confers water solubility and creates organized bi-layer and micelle structures. 
Phospholipases can also elicit 2nd messenger signaling cascades by releasing bioactive fatty acids 
(e.g. sphingolipids, eicosanoids) and/or polar head groups in response to growth or stress cues. 
External cell signaling cues can also be transmitted by lipids in the case of isoprenylation and 
subsequent transport of small GTPases to dock with G protein-coupled receptors (GPCRs) on the 
cell surface.   
Figure 2: Major lipid metabolic pathways altered in cancer cells.  Metabolic 
reprogramming during malignant transformation mimics autonomous growth signaling in 
unicellular organisms. Common oncogenes in the PI3K/Akt/MTOR pathway, are often mutated 
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or upregulated due to their presence downstream of external growth factors and their ability to 
re-route cellular carbon sources toward fatty acid utilization as an energy source. Cancer cells 
can also supply the TCA cycle from glucose via aberrant glycolysis and from glutamine via IDH 
mutations, although the contributions of these pathways differ greatly depending on the energy 
needs of the cell. The transcription factor Myc promotes many malignant processes in cancer 
cells because it is a master regulator capable of triggering survival pathways in response to 
hypoxia and nutrient deprivation. Hypoxic conditions are a factor in many solid tumors and 
influence the local tumor microenvironment by dampening the immune response and activating 
hypoxia-inducible factor-1α (HIF1α), which among other things, initiates the regulatory function 
of sterol regulatory element binding protein 1 (SREBP-1) on fatty acid synthesis. Free fatty acids 
such as palmitate are used as energy sources or converted to bioactive eicosanoids to dampen the 
immune response and stabilize the ER stress that can result from saturated fatty acid 
accumulation.
Figure 3:  Changes in lipid metabolism in response to oncolytic viral treatment of Syrian 
hamster carcinomas. The oncolytic viral treatment induces coagulative necrosis, which is seen as 
hypo-intense areas within the tumor on T2-weighted MR image. In vivo MRS from the voxel 
(overlaid on the image) is shown on the right demonstrating resonances from unsaturated fatty 
acids, taurine and choline. No changes in PUFA resonances were observed in coagulative 
necrosis resulting from oncolytic viral treatment. Reprinted with permission from (138). 
Figure 4. A) Confocal micrographs of SKOV3.ip cells treated for 48 h with cisplatin 
(CDDP) show increased lipid droplets as measured by Nile red staining, compared to untreated 
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controls (CTRL). Fixed cells were counterstained with phalloidin 488 for actin (green) and DAPI 
for nuclei (blue). Scale bar represents 23.8 μm. (B) 1H NMR spectra of intact SKOV3.ip cells 
treated with 5 mM CDDP for 48 h (red) show increases in mobile lipids compared with untreated 
control cells (black). Labeled lipid resonances include: methine protons at 5.3 ppm (-CH=CH-); 
fatty chain methylene group at 1.3 ppm (-(CH2)n)- ; methyl group at 0.9 ppm (-CH3) ; and total 
choline (tCho) at 3.2 ppm (-N.(CH3)3). Reprinted with permission from (150). 
Figure 5: Increased lipids in response to choline kinase inhibition as an alternate therapy 
for the treatment of gliomas. In vivo MRS from an untreated F98 rat glioma (bottom spectrum) 
and after 5 days of treatment with a choline kinase inhibitor, MN58b (top spectrum). Increased 
mono-unsaturated lipid peaks (1.3 ppm) are evident with treatment. In addition, a significant 
increase in the poly-unsaturated fatty acids (PUFA, 2.8 ppm), indicating apoptotic cell death. As 
expected, a decrease in the total choline (tCho) peak was also observed in response to choline 
kinase inhibition. The MR image demonstrates placement of the voxel for MRS studies. 
Reprinted with permission from (114).
Figure 6: Single voxel 1H MR spectra from a GL261 tumor implanted into a mouse 
brain. Treatment with three cycles of temozolomide led to significant (*) increases in mobile 
lipid:Cre and tCho:Cre resonances at 28 days post inoculation (left) compared to spectra 
acquired before treatment (tight). Labeled resonances: Cho (choline: 3.2 ppm, Cre (creatine): 3.3 
ppm, MLs (mobile lipid methylenes): 1.3 ppm, PUFAs: 2.8 ppm. Reprinted with permission 
from (128). 
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Figure 7: Chemical structure of the common PET tracers used for detection of lipid 
metabolism. The radioactive isotope is denoted in red. 
Figure 8: MALDI-MSI images and corresponding H&E sections from human colorectal 
tumors (A-C) and adjacent tumor free regions (D-F). A selective projection of m/z 478.3 onto 
MALDI-MSI images reveals elevations in 1-palmitoyl-lysophosphatidylcholine in cancer-
containing areas compared to the non-tumor bearing tissue sections. Elevations in m/z 504.3, 
representing 1-oleoyl-lysophosphatidylcholine, were also observed in this study. Reprinted with 
permission from (203).   
Figure 9: In vivo NIR fluorescence imaging of phospholipase activity using the PC-PLC 
activatable probe Pyro-PL-BHQ in DU145 prostate tumor xenografts. Each mouse received 80 
nmol i.v. of (A) Pyro-PtdEtn, a permanently fluorescent analog used as a control, (B) Pyro-
PtdEtn-BHQ or (C) Pyro-PtdEtn-BHQ plus pre- and post- injections of the PC-PLC inhibitor 
D609. The fluorescence intensity from Pyro-PL-BHQ activation peaked at 6-7 h, and was 
inhibited by D609 treatment. Fluorescence persisted for up to 31 h in tumor tissue (T) excised 
from mice when compared to muscle (M) control. Reprinted with permission from (112).
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Figure 1: Lipid metabolism pathways in the cell. Glucose transported into the cell is metabolized to pyruvate 
via the glycolytic pathway, and can be fed into the tricarboxylic acid (TCA) cycle for ATP production in the 
mitochondria. Citrate from the TCA cycle or from exogenous sources is converted to Acetyl-CoA in the 
cytoplasm and can be used for cholesterol or fatty acid (e.g. palmitate) biosynthesis. Cholesterol produced 
in this fashion can be used to synthesize membranes or be incorporated into sterols. Fatty acids can be 
desaturated or extended and then incorporated into triglycerides or incorporated into phospholipids via the 
Kennedy Pathway. Cholesterol and triglycerides fatty acids can also be taken up through specific transport 
mechanisms. The resulting lipid droplets, shown in the inset, contain fatty acids stored in phospholipid and 
fatty acid form that can be mobilized by phospholipases and lipases, respectively. Beta-oxidation (β-Ox) of 
free fatty acids from lipid droplets can be triggered to meet energy needs. In place of the third acyl group 
(Acyl3) attached to the glycerol moiety of triacylglycerides (orange oval), phospholipids have a 
phosphorylated polar head group (yellow sphere) that confers water solubility and creates organized bi-layer 
and micelle structures. Phospholipases can also elicit 2nd messenger signaling cascades by releasing 
bioactive fatty acids (e.g. sphingolipids, eicosanoids) and/or polar head groups in response to growth or 
stress cues. External cell signaling cues can also be transmitted by lipids in the case of isoprenylation and 
subsequent transport of small GTPases to dock with G protein-coupled receptors (GPCRs) on the cell 
surface.   
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Figure 2: Major lipid metabolic pathways altered in cancer cells.  Metabolic reprogramming during malignant 
transformation mimics autonomous growth signaling in unicellular organisms. Common oncogenes in the 
PI3K/Akt/MTOR pathway, are often mutated or upregulated due to their presence downstream of external 
growth factors and their ability to re-route cellular carbon sources toward fatty acid utilization as an energy 
source. Cancer cells can also supply the TCA cycle from glucose via aberrant glycolysis and from glutamine 
via IDH mutations, although the contributions of these pathways differ greatly depending on the energy 
needs of the cell. The transcription factor Myc promotes many malignant processes in cancer cells because it 
is a master regulator capable of triggering survival pathways i  response to hypoxia and nutrient 
deprivation. Hypoxic conditions are a factor in many solid tumors and influence the local tumor 
microenvironment by dampening the immune response and activating hypoxia-inducible factor-1α (HIF1α), 
which among other things, initiates the regulatory function of sterol regulatory element binding protein 1 
(SREBP-1) on fatty acid synthesis. Free fatty acids such as palmitate are used as energy sources or 
converted to bioactive eicosanoids to dampen the immune response and stabilize the ER stress that can 
result from saturated fatty acid accumulation. 
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Figure 3:  Changes in lipid metabolism in response to oncolytic viral treatment of Syrian hamster 
carcinomas. The oncolytic viral treatment induces coagulative necrosis, which is seen as hypo-intense areas 
within the tumor on T2-weighted MR image. In vivo MRS from the voxel (overlaid on the image) is shown on 
the right demonstrating resonances from unsaturated fatty acids, taurine and choline. Unlike the increased 
PUFA resonances observed during apoptosis (Figure 3), no No changes in PUFA resonances were observed in 
coagulative necrosis resulting from oncolytic viral treatment. Reprinted with permission from (138). 
279x209mm (72 x 72 DPI) 
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Figure 4. A) Confocal micrographs of SKOV3.ip cells treated for 48 h with cisplatin (CDDP) show increased 
lipid droplets as measured by Nile red staining, compared to untreated controls (CTRL). Fixed cells were 
counterstained with phalloidin 488 for actin (green) and DAPI for nuclei (blue). Scale bar represents 23.8 
μm. (B) 1H NMR spectra of intact SKOV3.ip cells treated with 5 mM CDDP for 48 h (red) show increases in 
mobile lipids compared with untreated control cells (black). Labeled lipid resonances include: methine 
protons at 5.3 ppm (-CH=CH-); fatty chain methylene group at 1.3 ppm (-(CH2)n)- ; methyl group at 0.9 
ppm (-CH3) ; and total choline (tCho) at 3.2 ppm (-N.(CH3)3). Reprinted with permission from (150). 
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Figure 5: Increased lipids in response to choline kinase inhibition as an alternate therapy for the treatment 
of gliomas. In vivo MRS from an untreated F98 rat glioma (bottom spectrum) and after 5 days of treatment 
with a choline kinase inhibitor, MN58b (top spectrum). Increased mono-unsaturated lipid peaks (1.3 ppm) 
are evident with treatment. In addition, a significant increase in the poly-unsaturated fatty acids (PUFA, 2.8 
ppm), indicating apoptotic cell death. As expected, a decrease in the total choline (tCho) peak was also 
observed in response to choline kinase inhibition. The MR image demonstrates placement of the voxel for 
MRS studies. Reprinted with permission from (114). 
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Figure 6: Single voxel 1H MR spectra from a GL261 tumor implanted into a mouse brain. Treatment with 
three cycles of temozolomide led to significant (*) increases in mobile lipid:Cre and tCho:Cre resonances at 
28 days post inoculation (left) compared to spectra acquired before treatment (tight). Labeled resonances: 
Cho (choline: 3.2 ppm, Cre (creatine): 3.3 ppm, MLs (mobile lipid methylenes): 1.3 ppm, PUFAs: 2.8 ppm. 
Reprinted with permission from (128). 
279x209mm (72 x 72 DPI) 
Page 124 of 128
http://mc.manuscriptcentral.com/nbm
NMR in Biomedicine - For Peer Review Only
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Peer Review Only
 
Figure 7: Chemical structure of the common PET tracers used for detection of lipid metabolism. The 
radioactive isotope is denoted in red. 
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Figure 8: MALDI-MSI images and corresponding H&E sections from human colorectal tumors (A-C) and 
adjacent tumor free regions (D-F). A selective projection of m/z 478.3 onto MALDI-MSI images reveals 
elevations in 1-palmitoyl-lysophosphatidylcholine in cancer-containing areas compared to the non-tumor 
bearing tissue sections. Elevations in m/z 504.3, representing 1-oleoyl-lysophosphatidylcholine, were also 
observed in this study. Reprinted with permission from (203).   
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Figure 9: In vivo NIR fluorescence imaging of phospholipase activity using the PC-PLC activatable probe 
Pyro-PL-BHQ in DU145 prostate tumor xenografts. Each mouse received 80 nmol i.v. of (A) Pyro-PtdEtn, a 
permanently fluorescent analog used as a control, (B) Pyro-PtdEtn-BHQ or (C) Pyro-PtdEtn-BHQ plus pre- 
and post- injections of the PC-PLC inhibitor D609. The fluorescence intensity from Pyro-PL-BHQ activation 
peaked at 6-7 h, and was inhibited by D609 treatment. Fluorescence persisted for up to 31 h in tumor tissue 
(T) excised from mice when compared to muscle (M) control. Reprinted with permission from (112). 
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Graphical Abstract:Imaging of Cancer Lipid Metabolism in Response to 
Therapy
Sean Arlauckas, Elizabeth A. Browning, Harish Poptani, E. James Delikatny
Abstract
Lipids play a critical role in biological systems ranging from structural integrity to 
signaling, energy, defense and communication.  This article reviews lipids and lipid metabolic 
pathways altered in cancer development and their changes in response to therapy that are 
amenable for study by imaging. We focus first on MR spectroscopy, which was instrumental in 
defining the field of lipid imaging (Figure) and still plays a major role, followed by 
complementary molecular imaging methods including PET, mass spectroscopic imaging and 
optical imaging.  
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